Track market-moving stories before they get noisy

Newell Brands Inc. (NASDAQ:NWL – Get Free Report) shares were up 4.4% during mid-day trading on Friday . The company traded as high as $6.15 and last traded at $6.14. 633,350 shares traded hands during trading, a decline of 92% from the average daily volume of 8,028,082 shares. The stock had previously closed at $5.88.

Analyst Upgrades and Downgrades A number of equities research analysts recently weighed in on the stock. Royal Bank Of Canada lifted their price objective on shares of Newell Brands from $4.00 to $5.00 and gave the company a “sector perform” rating in a report on Monday, August 3rd. Zacks Research upgraded Newell Brands from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $6.00 price objective on shares of Newell Brands in a research note on Monday, August 3rd. Citigroup raised their price objective on Newell Brands from $5.50 to $6.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Finally, Morgan Stanley reaffirmed an “underweight” rating and set a $5.75 target price on shares of Newell Brands in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Newell Brands currently has a consensus rating of “Hold” and an average target price of $6.66.

Check Out Our Latest Analysis on NWL

Newell Brands Stock Performance The business has a 50-day moving average price of $5.66 and a 200-day moving average price of $4.64. The company has a quick ratio of 0.59, a current ratio of 1.11 and a debt-to-equity ratio of 1.85. The firm has a market capitalization of $2.63 billion, a price-to-earnings ratio of -11.64, a P/E/G ratio of 1.52 and a beta of 0.88. Newell Brands (NASDAQ:NWL – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.22. The business had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.98 billion. Newell Brands had a negative net margin of 3.05% and a positive return on equity of 12.31%. Newell Brands’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.24 EPS. Newell Brands has set its Q3 2026 guidance at 0.180-0.200 EPS and its FY 2026 guidance at 0.730-0.770 EPS. As a group, sell-side analysts forecast that Newell Brands Inc. will post 0.76 earnings per share for the current year.

Newell Brands Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Monday, August 31st will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 4.5%. The ex-dividend date of this dividend is Monday, August 31st. Newell Brands’s dividend payout ratio (DPR) is -52.83%.

Insider Buying and Selling at Newell Brands In other Newell Brands news, insider Bradford R. Turner sold 100,000 shares of Newell Brands stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $6.16, for a total value of $616,000.00. Following the completion of the transaction, the insider owned 433,398 shares of the company’s stock, valued at approximately $2,669,731.68. The trade was a 18.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.64% of the stock is currently owned by company insiders.

Institutional Trading of Newell Brands Several institutional investors have recently modified their holdings of NWL. Royal Bank of Canada raised its position in shares of Newell Brands by 29.2% in the first quarter. Royal Bank of Canada now owns 775,131 shares of the company’s stock valued at $4,800,000 after buying an additional 175,178 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Newell Brands by 47.3% during the first quarter. Goldman Sachs Group Inc. now owns 563,984 shares of the company’s stock worth $3,497,000 after acquiring an additional 181,113 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Newell Brands by 13.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,302,018 shares of the company’s stock worth $8,073,000 after acquiring an additional 153,658 shares during the last quarter. Focus Partners Wealth grew its stake in Newell Brands by 47.0% during the 1st quarter. Focus Partners Wealth now owns 63,846 shares of the company’s stock valued at $396,000 after acquiring an additional 20,406 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in Newell Brands during the 1st quarter valued at about $1,326,000. Institutional investors and hedge funds own 92.50% of the company’s stock.

Newell Brands Company Profile (Get Free Report)

Newell Brands Inc, trading on NASDAQ under the ticker NWL, is a global consumer goods company known for its diverse portfolio of household, commercial, and specialty products. Formed through the merger of Newell Rubbermaid and Jarden Corporation in 2016, the company traces its roots back to Newell Manufacturing, which was founded in 1903. Headquartered in Atlanta, Georgia, Newell Brands has built a reputation for widely recognized brands spanning multiple consumer categories.

The company’s business activities are organized across several segments, including writing and creative expression, home solutions, commercial products, and outdoor recreation.

See Also Five stocks we like better than Newell Brands From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash Venture Into High-Volatility Corners of the Market With These 3 ETFs 3 Retail Stocks to Watch After a Big Consumer Earnings Week Receive News & Ratings for Newell Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Newell Brands and related companies with MarketBeat.com's FREE daily email newsletter.

Bamco Inc. NY purchased a new position in shares of FactSet Research Systems Inc. (NYSE:FDS – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 4,200,856 shares of the business services provider’s stock, valued at approximately $966,533,000. FactSet Research Systems comprises approximately 1.5% of Bamco Inc. NY’s investment portfolio, making the stock its 14th largest holding. Bamco Inc. NY owned 11.81% of FactSet Research Systems at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Jones Financial Companies Lllp grew its position in shares of FactSet Research Systems by 5.6% in the first quarter. Jones Financial Companies Lllp now owns 1,727 shares of the business services provider’s stock valued at $785,000 after purchasing an additional 91 shares during the period. Empowered Funds LLC grew its holdings in FactSet Research Systems by 27.6% in the 1st quarter. Empowered Funds LLC now owns 972 shares of the business services provider’s stock valued at $442,000 after buying an additional 210 shares during the period. Geneos Wealth Management Inc. increased its stake in shares of FactSet Research Systems by 188.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 98 shares of the business services provider’s stock valued at $45,000 after acquiring an additional 64 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of FactSet Research Systems by 58.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 138 shares of the business services provider’s stock worth $62,000 after acquiring an additional 51 shares during the period. Finally, Cerity Partners LLC boosted its position in shares of FactSet Research Systems by 15.6% in the second quarter. Cerity Partners LLC now owns 5,247 shares of the business services provider’s stock worth $2,347,000 after acquiring an additional 707 shares during the last quarter. 91.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades A number of equities research analysts have issued reports on FDS shares. BMO Capital Markets boosted their price target on FactSet Research Systems from $257.00 to $275.00 and gave the company a “market perform” rating in a research report on Thursday, July 2nd. Morgan Stanley boosted their target price on FactSet Research Systems from $228.00 to $230.00 and gave the stock an “equal weight” rating in a report on Thursday, July 2nd. UBS Group reissued a “buy” rating on shares of FactSet Research Systems in a research report on Wednesday, July 22nd. The Goldman Sachs Group cut shares of FactSet Research Systems from a “sell” rating to an “underweight” rating in a research report on Thursday, June 18th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a $240.00 price objective on shares of FactSet Research Systems in a research report on Thursday, July 2nd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, ten have given a Hold rating and six have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $253.00.

Read Our Latest Stock Analysis on FactSet Research Systems FactSet Research Systems Trading Down 0.4% Shares of NYSE:FDS opened at $295.02 on Thursday. The company has a quick ratio of 0.68, a current ratio of 0.68 and a debt-to-equity ratio of 0.44. The company’s 50-day moving average price is $260.88 and its 200 day moving average price is $235.01. The company has a market cap of $10.49 billion, a PE ratio of 19.43, a P/E/G ratio of 1.99 and a beta of 0.70. FactSet Research Systems Inc. has a fifty-two week low of $185.00 and a fifty-two week high of $384.33.

FactSet Research Systems (NYSE:FDS – Get Free Report) last announced its quarterly earnings results on Wednesday, July 1st. The business services provider reported $4.53 EPS for the quarter, beating the consensus estimate of $4.44 by $0.09. The company had revenue of $622.92 million for the quarter, compared to analyst estimates of $617.91 million. FactSet Research Systems had a net margin of 23.21% and a return on equity of 30.68%. FactSet Research Systems’s revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the business earned $4.27 earnings per share. FactSet Research Systems has set its FY 2026 guidance at 17.250-17.750 EPS. Sell-side analysts anticipate that FactSet Research Systems Inc. will post 17.76 earnings per share for the current year.

FactSet Research Systems Announces Dividend The business also recently announced a quarterly dividend, which will be paid on Thursday, September 17th. Investors of record on Monday, August 31st will be given a $1.16 dividend. This represents a $4.64 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date is Monday, August 31st. FactSet Research Systems’s dividend payout ratio is currently 30.57%.

FactSet Research Systems Company Profile (Free Report)

FactSet Research Systems Inc operates as a global provider of integrated financial data and analytics to the investment community. Founded in 1978 and headquartered in Norwalk, Connecticut, the company offers a unified platform that aggregates content from thousands of sources, delivering real-time and historical market data, company fundamentals, estimates, fixed-income information and proprietary analytics to portfolio managers, research analysts, investment bankers and risk officers.

The company’s core products include the FactSet Workstation, an application offering customizable screening, charting, portfolio analysis and news; APIs and data feeds for seamless integration into proprietary systems; and cloud-based solutions for thematic research and quantitative strategies.

Further Reading Five stocks we like better than FactSet Research Systems Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise Alcoa’s Gallium Project Opens a New Door Beyond Aluminum Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech Can Tesla’s Flying Roadster Distract From Its Real Risks?

Receive News & Ratings for FactSet Research Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FactSet Research Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Can we declare a winner in the air taxi race yet? In a competition led by innovators Archer Aviation (ACHR -3.04%) and Joby Aviation (JOBY -2.38%), there isn't a clear champion yet, but Joby appears to have the lead. It pulled ahead of Archer in reaching the final stage of Federal Aviation Administration (FAA) certification, but both companies still have plans to begin U.S. operations under a federal pilot program this year.

Premium Feature

Moneyball Superscore

66/100

Today's Change

(

-2.38

%) $

-0.17

Current Price

$

6.98

Shares of Joby have plummeted nearly 50% over the past year. The company has made progress in increasing revenue while it continues to pursue a viable commercial air taxi business. Of the company's nearly $39 million in revenue in the second quarter of 2026, roughly $36 million came entirely from its subsidiary, Blade. Joby also recently announced it'll acquire the defense-tech firm Resonant Sciences in a move that'll substantially boost revenue.

The company has an enviable cash position of approximately $2.3 billion. That's an important runway for a business with high cash burn and a core product that hasn't officially launched.

Image source: The Motley Fool.

Full certification from the FAA will give Joby the biggest lift and reduce the execution risk for investors. From there, it'll still be years before commercial air taxis hit the mainstream, but if anyone is going to do it, there's a solid chance it's going to be Joby Aviation. With its partnership with Uber Technologies and plans to launch among Dubai's ultra-wealthy, Joby is the frontrunner.

Naming a winner in this race is premature. Investors should continue to monitor Joby's progress with regulators. Both Joby and Archer still need to prove they can mass-produce their aircraft and turn a profit. The stakes are sky-high, but so is the potential upside if air taxis become a widespread mode of transportation.

Catie Hogan has no position in any of the stocks mentioned. The Motley Fool recommends Uber Technologies. The Motley Fool has a disclosure policy.

Algert Global LLC grew its stake in Zurn Elkay Water Solutions Cor (NYSE:ZWS – Free Report) by 51.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 169,860 shares of the company’s stock after acquiring an additional 57,720 shares during the quarter. Algert Global LLC owned 0.10% of Zurn Elkay Water Solutions Cor worth $8,583,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of ZWS. Kilter Group LLC purchased a new stake in shares of Zurn Elkay Water Solutions Cor during the second quarter valued at approximately $25,000. Advisory Services Network LLC bought a new position in shares of Zurn Elkay Water Solutions Cor during the 3rd quarter valued at $25,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Zurn Elkay Water Solutions Cor during the 2nd quarter valued at $27,000. Kemnay Advisory Services Inc. purchased a new position in shares of Zurn Elkay Water Solutions Cor in the 4th quarter worth $35,000. Finally, Hantz Financial Services Inc. grew its holdings in shares of Zurn Elkay Water Solutions Cor by 138.9% in the fourth quarter. Hantz Financial Services Inc. now owns 805 shares of the company’s stock worth $37,000 after acquiring an additional 468 shares during the period. Hedge funds and other institutional investors own 83.33% of the company’s stock.

Wall Street Analyst Weigh In A number of analysts have commented on ZWS shares. Robert W. Baird set a $58.00 target price on shares of Zurn Elkay Water Solutions Cor in a report on Thursday, July 30th. Zacks Research raised shares of Zurn Elkay Water Solutions Cor from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. Weiss Ratings restated a “buy (b)” rating on shares of Zurn Elkay Water Solutions Cor in a research note on Friday, July 24th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $55.00 target price on shares of Zurn Elkay Water Solutions Cor in a report on Wednesday, July 29th. Finally, Stifel Nicolaus boosted their price target on Zurn Elkay Water Solutions Cor from $56.00 to $62.00 and gave the company a “buy” rating in a report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $57.22.

Check Out Our Latest Analysis on ZWS Insider Buying and Selling In other news, Director Jacques Donavon Butler acquired 2,016 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was acquired at an average price of $49.60 per share, for a total transaction of $99,993.60. Following the completion of the transaction, the director owned 37,487 shares in the company, valued at approximately $1,859,355.20. The trade was a 5.68% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.40% of the company’s stock.

NYSE ZWS opened at $49.13 on Thursday. The business’s 50 day moving average price is $49.47 and its 200-day moving average price is $48.82. Zurn Elkay Water Solutions Cor has a fifty-two week low of $43.06 and a fifty-two week high of $55.00. The company has a market cap of $8.15 billion, a P/E ratio of 30.33, a P/E/G ratio of 1.79 and a beta of 1.04. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.13 and a current ratio of 3.05.

Zurn Elkay Water Solutions Cor (NYSE:ZWS – Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.03. The firm had revenue of $491.00 million for the quarter, compared to analysts’ expectations of $483.04 million. Zurn Elkay Water Solutions Cor had a net margin of 15.45% and a return on equity of 18.01%. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.42 earnings per share. Sell-side analysts predict that Zurn Elkay Water Solutions Cor will post 1.82 earnings per share for the current year.

Zurn Elkay Water Solutions Cor Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, September 4th. Investors of record on Thursday, August 20th will be issued a dividend of $0.11 per share. This represents a $0.44 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, August 20th. Zurn Elkay Water Solutions Cor’s dividend payout ratio (DPR) is 27.16%.

About Zurn Elkay Water Solutions Cor (Free Report)

Zurn Elkay Water Solutions Corp, trading on the NYSE under the ticker ZWS, is a global provider of water delivery and plumbing products. The company was established in October 2022 through a spin-off from Rexnord Corp, creating a standalone business focused on designing, manufacturing and marketing water system components for residential, commercial and industrial customers.

Through its Zurn segment, the company offers solutions for water delivery, drainage and waste evacuation. Product lines include valves, hydrants, backflow prevention devices, piping systems, fittings and commercial waste stations.

Recommended Stories Five stocks we like better than Zurn Elkay Water Solutions Cor Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise Alcoa’s Gallium Project Opens a New Door Beyond Aluminum Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech Can Tesla’s Flying Roadster Distract From Its Real Risks? Want to see what other hedge funds are holding ZWS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zurn Elkay Water Solutions Cor (NYSE:ZWS – Free Report).

Receive News & Ratings for Zurn Elkay Water Solutions Cor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zurn Elkay Water Solutions Cor and related companies with MarketBeat.com's FREE daily email newsletter.

A month has gone by since the last earnings report for Manhattan Associates (MANH - Free Report) . Shares have added about 5.8% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Manhattan Associates due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts.

MANH Q2 Earnings Beat Estimates, Cloud Growth Fuels RevenuesManhattan Associates reported second-quarter 2026 non-GAAP adjusted earnings of $1.39 per share, beating the Zacks Consensus Estimate by 6.11% and increasing 6.1% year over year.

Revenues beat the consensus mark by 3.6% and climbed 9.3% year over year to $297.8 million. Management reported better-than-expected revenues and profitability, accelerating cloud growth and a sharp increase in remaining performance obligations.

RPO increased to $2.47 billion as of June 30, 2026, compared to $2.35 billion as of March 31, 2026, representing 23% growth year over year.

MANH's Q2 Top-Line DetailsCloud subscription revenues surged 26.2% year over year to $126.7 million. Software license revenues rose 25.9% year over year to $1.9 million, reflecting stronger deal activity within a still small revenue base. Maintenance revenues slipped 12.9% year over year to $30.5 million as customers continued migrating to cloud-native deployments. Services revenues grew 3.2% year over year to $133.0 million. Hardware revenues declined 14.4% year over year to $5.6 million.

On a geographic basis, Americas revenues grew 9.9% year over year to $227 million. EMEA revenues increased 5.9% year over year to $55.4 million. APAC revenues rose 14% year over year to $15.4 million.

Operating Details of MANHGAAP total costs and expenses rose 16.6% year over year to $231.6 million, driven in part by an $8.3 million restructuring charge tied to the June headcount reduction. GAAP operating income declined 10.2% year over year to $66.2 million. Non-GAAP adjusted operating income increased 2.7% year over year to $103.9 million.

GAAP net income declined 11.3% year over year to $50.4 million while GAAP EPS fell 8.6% year over year to 85 cents, reflecting the restructuring expense and elevated equity-based compensation costs relative to the year-ago period. Non-GAAP adjusted EPS grew 6.1% year over year to $1.39.

MANH's Q2 Balance Sheet & Cash FlowCash flow from operations grew 22.6% year over year to $90.7 million. Days Sales Outstanding improved to 67 days at June 30, 2026 from 72 days at March 31, 2026. Cash totaled $186.1 million at June 30, 2026, down 17.7% from $226.1 million at March 31, 2026, largely reflecting continued share repurchase activity.

Capital expenditures were $1 million in the second quarter of 2026, down 74.7% year over year from $4 million in the second quarter of 2025. Manhattan Associates ended the quarter with no debt on its balance sheet.

During the three months ended June 30, 2026, the company repurchased approximately 874,029 shares for a total of $125.0 million. Over the six months ended June 30, 2026, total repurchases reached 1,917,341 shares for $275.0 million. Approximately $225 million remained under the existing March 2026 repurchase authority as of quarter end.

MANH's 2026 GuidanceFor full-year 2026, Manhattan Associates raised guidance for total revenues to a range of $1.16 billion to $1.166 billion, implying 7-8% growth. GAAP operating margin guidance is 24.2% to 24.4% while non-GAAP adjusted operating margin is expected at 35-35.2%. GAAP EPS is projected at $3.59-$3.65 while non-GAAP adjusted EPS is guided at $5.44-$5.5, representing 8-9% growth.

Full-year 2026 cloud revenue guidance was raised, with the midpoint increasing to $505.5 million, implying approximately 24% growth.

How Have Estimates Been Moving Since Then?It turns out, estimates review have trended upward during the past month.

VGM ScoresCurrently, Manhattan Associates has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Manhattan Associates has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerManhattan Associates belongs to the Zacks Computer - Software industry. Another stock from the same industry, Pegasystems (PEGA - Free Report) , has gained 9.3% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.

Pegasystems reported revenues of $420.72 million in the last reported quarter, representing a year-over-year change of +9.4%. EPS of $0.35 for the same period compares with $0.28 a year ago.

Pegasystems is expected to post earnings of $0.48 per share for the current quarter, representing a year-over-year change of +60%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Pegasystems. Also, the stock has a VGM Score of B.

Injective lands on DexScreenerThe @Injective ecosystem is now accessible on @dexscreener, marking another step in the network's ongoing push to broaden its market infrastructure. The integration gives traders and analysts a single terminal for tracking $INJ activity, surfacing real-time token data and liquidity metrics across the Injective network.

DexScreener is a widely used DEX analytics platform that provides pricing, volume, and liquidity data for assets traded on decentralized exchanges. That includes tokens traded on platforms already active within the ecosystem, extending the reach of on-chain discovery tools to Injective's growing user base.

What it means for the Injective ecosystemInjective is Its architecture is built around an order book model rather than an automated market maker, which

The DexScreener integration builds on that foundation by aggregating token activity and liquidity data in one place. For a network that has been steadily expanding its roster of supported applications and cross-chain connections, improved data visibility is a practical step toward broader accessibility.

Injective's interoperability also plays into the integration's utility. meaning assets from across the wider crypto market can flow into and out of the ecosystem. As that cross-chain activity grows, real-time analytics tools become more important for users trying to track emerging opportunities.

The listing on DexScreener reflects a pattern common to expanding Layer 1 networks: pairing technical development with the data infrastructure traders rely on when evaluating new markets.

Sources:
DexScreener: Injective Network
Gemini Cryptopedia: Injective Protocol (INJ)

@injective has announced it is working with @circle and teams across the @cosmos ecosystem to move legacy $USDC versions onto the native issuance that Circle launched on Injective in May, with the broader migration now targeting September.

The legacy versions in scope include Noble-issued USDC and bridged variants that have circulated across Cosmos chains. The goal is to consolidate them onto a single, natively issued standard backed directly by Circle, removing the fragmentation that has long complicated stablecoin use across interchain applications.

How the native issuance works The foundation for this shift was laid on May 7, 2026, when native USDC and Circle's Cross-Chain Transfer Protocol (CCTP) went live on the Injective mainnet. CCTP allows USDC to move natively across blockchains, meaning tokens are burned on the source chain and minted on the destination chain rather than locked in a bridge contract. It was also Circle's first MultiVM issuance of the token.

The integration was intended to ensure continued USDC availability across Cosmos chains after Noble announced its migration plans to a dedicated EVM Layer 1 and positioned its Cosmos SDK chain into maintenance mode. By taking over that position, Injective is expected to absorb more than $100 million in stablecoin issuance connected to the ecosystem.

Cosmos Hub commitment and rollout Four days after launch, the Cosmos Hub adopted the Injective issuance as the ecosystem's reference USDC under a minimum four-year commitment, with Skip:Go set to treat it as the default USDC denomination. Cosmos Hub, Cosmos Labs, and Skip Protocol confirmed that Injective-issued USDC will route through the Inter-Blockchain Communication (IBC) protocol.

The migration rolls out over the coming months, with dYdX going first, and Cosmos Labs coordinating the rollout for additional chains and applications across the ecosystem. Migration tools are also being prepared for chains and DeFi platforms transitioning from previous USDC liquidity providers. For users, the frontend experience is expected to remain mostly unchanged.

A portion of fees generated from Injective USDC activity will also be allocated to programmatically buy back ATOM, the native token of the Cosmos Hub.

Sources
Injective: USDC Adopted by Cosmos and dYdX as Canonical Stablecoin Standard
Crypto Times: Cosmos Hub Adopts Injective USDC as Primary Stablecoin
Crypto Briefing: Injective Initiates Migration of Exchange dApps to USDC Standard

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - August 26, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Beazer Homes USA, Inc. ("Bowman" or the "Company") (NYSE: BZH) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Dream Finders Homes, Inc. (NYSE: DFH) for $33.50 for each share of Beazer common stock in an all-cash transaction at an enterprise value of approximately $2.2 billion.

The investigation concerns whether the Bowman Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.

If you own shares of Bowman stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at [email protected], visit https://www.brodskysmith.com/cases/beazer-homes-usa-inc-nyse-bzh/, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/311604

Source: Brodsky & Smith

Artia Global Partners LP purchased a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 65,122 shares of the medical research company’s stock, valued at approximately $13,803,000. Quest Diagnostics comprises approximately 2.5% of Artia Global Partners LP’s holdings, making the stock its 12th largest holding. Artia Global Partners LP owned 0.06% of Quest Diagnostics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Key Financial Inc boosted its position in shares of Quest Diagnostics by 1,728.6% during the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 121 shares in the last quarter. Ancora Advisors LLC acquired a new stake in Quest Diagnostics during the 2nd quarter valued at $29,000. Quattro Advisors LLC acquired a new stake in Quest Diagnostics during the 4th quarter valued at $25,000. Sittner & Nelson LLC purchased a new stake in shares of Quest Diagnostics in the fourth quarter valued at $29,000. Finally, DV Equities LLC purchased a new stake in shares of Quest Diagnostics in the fourth quarter valued at $27,000. Institutional investors own 88.06% of the company’s stock.

Quest Diagnostics Price Performance NYSE:DGX opened at $244.78 on Thursday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46. The company has a fifty day moving average price of $222.01 and a 200 day moving average price of $206.46. Quest Diagnostics Incorporated has a one year low of $171.18 and a one year high of $246.00. The stock has a market cap of $27.02 billion, a P/E ratio of 25.99, a PEG ratio of 2.25 and a beta of 0.56.

Quest Diagnostics (NYSE:DGX – Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, beating analysts’ consensus estimates of $2.82 by $0.30. The business had revenue of $3.04 billion during the quarter, compared to analyst estimates of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.Quest Diagnostics’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Analysts anticipate that Quest Diagnostics Incorporated will post 11.15 earnings per share for the current year. Quest Diagnostics Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be paid a $0.86 dividend. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Tuesday, October 6th. Quest Diagnostics’s dividend payout ratio (DPR) is 36.52%.

Insiders Place Their Bets In related news, SVP Mark E. Delaney sold 1,600 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total transaction of $376,288.00. Following the completion of the sale, the senior vice president directly owned 10,335 shares of the company’s stock, valued at $2,430,585.30. The trade was a 13.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the completion of the transaction, the senior vice president owned 13,510 shares in the company, valued at $2,702,000. This represents a 37.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 19,747 shares of company stock valued at $3,947,088. 0.88% of the stock is currently owned by insiders.

Analyst Ratings Changes Several brokerages recently issued reports on DGX. Mizuho increased their price objective on Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. UBS Group lifted their target price on Quest Diagnostics from $220.00 to $232.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Barclays raised their price target on shares of Quest Diagnostics from $230.00 to $250.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Wall Street Zen raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 28th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $245.00 price target on shares of Quest Diagnostics in a research note on Thursday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Quest Diagnostics has a consensus rating of “Moderate Buy” and an average target price of $235.31.

Check Out Our Latest Analysis on Quest Diagnostics

Quest Diagnostics Company Profile (Free Report)

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.

Further Reading Five stocks we like better than Quest Diagnostics Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise Alcoa’s Gallium Project Opens a New Door Beyond Aluminum Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech Can Tesla’s Flying Roadster Distract From Its Real Risks?

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Bank of New York Mellon Corp acquired a new stake in shares of Littelfuse, Inc. (NASDAQ:LFUS – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 189,632 shares of the technology company’s stock, valued at approximately $86,345,000. Bank of New York Mellon Corp owned about 0.75% of Littelfuse as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State of Wyoming bought a new stake in shares of Littelfuse in the 2nd quarter valued at approximately $740,000. Trifecta Capital Advisors LLC acquired a new stake in shares of Littelfuse in the 2nd quarter valued at $137,000. Oppenheimer Asset Management Inc. bought a new stake in shares of Littelfuse in the 2nd quarter worth about $2,341,000. Handelsbanken Fonder AB increased its position in shares of Littelfuse by 65.3% during the 2nd quarter. Handelsbanken Fonder AB now owns 3,745 shares of the technology company’s stock worth $1,705,000 after purchasing an additional 1,480 shares in the last quarter. Finally, Revolve Wealth Partners LLC bought a new position in Littelfuse during the 2nd quarter valued at about $234,000. 96.14% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades A number of equities research analysts recently weighed in on the company. Wall Street Zen raised Littelfuse from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Robert W. Baird lifted their price target on Littelfuse from $500.00 to $535.00 and gave the company an “outperform” rating in a report on Friday, June 5th. Needham & Company LLC reissued a “buy” rating and set a $520.00 price objective on shares of Littelfuse in a report on Monday, May 18th. Zacks Research downgraded shares of Littelfuse from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Weiss Ratings raised shares of Littelfuse from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 30th. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $465.83.

Check Out Our Latest Report on Littelfuse Insiders Place Their Bets In other Littelfuse news, Director Anthony Grillo sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $451.96, for a total transaction of $1,355,880.00. Following the completion of the sale, the director directly owned 64,928 shares in the company, valued at $29,344,858.88. This trade represents a 4.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 1.00% of the company’s stock.

Littelfuse Price Performance Shares of NASDAQ LFUS opened at $405.39 on Wednesday. The company has a fifty day moving average price of $434.26 and a 200 day moving average price of $406.40. The firm has a market cap of $10.30 billion, a PE ratio of -810.76, a PEG ratio of 2.13 and a beta of 1.49. The company has a current ratio of 2.76, a quick ratio of 2.00 and a debt-to-equity ratio of 0.20. Littelfuse, Inc. has a 1-year low of $233.36 and a 1-year high of $500.57.

Littelfuse (NASDAQ:LFUS – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The technology company reported $4.19 earnings per share for the quarter, topping analysts’ consensus estimates of $3.78 by $0.41. The firm had revenue of $738.78 million during the quarter, compared to the consensus estimate of $703.38 million. Littelfuse had a positive return on equity of 13.02% and a negative net margin of 0.31%.The business’s revenue was up 20.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.30 EPS. Littelfuse has set its Q3 2026 guidance at 4.850-5.050 EPS. Research analysts predict that Littelfuse, Inc. will post 15.78 earnings per share for the current fiscal year.

Littelfuse Increases Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th will be given a $0.80 dividend. The ex-dividend date of this dividend is Thursday, August 20th. This is a positive change from Littelfuse’s previous quarterly dividend of $0.75. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.8%. Littelfuse’s payout ratio is -640.00%.

Littelfuse Company Profile (Free Report)

Littelfuse, Inc is a global manufacturer of circuit protection, power control, and sensing technologies. Founded in 1927 and headquartered in Chicago, Illinois, the company develops and produces a broad range of products designed to safeguard electrical and electronic systems across a variety of end markets. Littelfuse’s offerings include fuses, semiconductors, relays, and sensors, all engineered to protect against overcurrent, overvoltage, and thermal events in demanding applications.

The company’s product portfolio is organized into key segments such as Automotive, Industrial & Electronics, and Power & Sensor.

Read More Five stocks we like better than Littelfuse Pathward’s Credit Scare Tests Its Comeback Story Wiring the AI Boom: Rumble’s $13.7B Pivot StoneX: Too Far Too Fast? DICK’s Sporting Goods Faces Pain Now for a Bigger Prize Want to see what other hedge funds are holding LFUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Littelfuse, Inc. (NASDAQ:LFUS – Free Report).

Receive News & Ratings for Littelfuse Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Littelfuse and related companies with MarketBeat.com's FREE daily email newsletter.

AI accelerators receive the headlines, but nearly every expanding computing system still pays Arm for architecture. Summary

Raymond James’ target offers approximately 11% upside from Tuesday’s price.

Arm Holdings ARM, the chip-architecture powerhouse sitting at the heart of smartphones and data centers, climbed approximately 2.3% to $244.27 Tuesday morning. Investor's Business Daily reported that Raymond James maintained its Outperform rating and boosted its price target to $272, betting that agentic AI will ignite another wave of server-CPU demand.

The growth is already landing. Arm's fiscal first-quarter revenue soared 22% to a record $1.29 billion. Royalty revenue jumped 22% to $715 million, licensing revenue surged 23% to $574 million and data-center royalties more than doubled. Better still, customer demand for the new Arm AGI CPU has already cleared $2 billion across fiscal 2027 and 2028.

Now comes the valuation test. Raymond James' $272 target leaves roughly 11.4% upside from the current price, suggesting plenty of AI optimism is already baked in. Arm's royalty model is a beauty because it can win across multiple competing chipmakers, but investors are paying up for that advantage. The shares trade 28.12% above their $190.65 GF Value estimate, leaving little room for data-center momentum to cool.

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

Highlights of the second quarter include:

Net income increased 10% to $65.6 million, and net income margin increased to 19% from 18% last year.Adjusted EBITDA increased 11% to $167.0 million, and Adjusted EBITDA margin increased to 48% from 46% last year.Revenue increased 8% to $350.7 million.Net income per diluted share rose 15% to $0.78 from $0.68 one year ago, and non-GAAP net income per diluted share increased 15% to $1.24.Total HSA Assets grew 14% to $37.9 billion.Returned $108.1 million to shareholders through stock repurchases.
DRAPER, Utah, Aug. 27, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the largest independent health savings account ("HSA") custodian by account volume and a leader in consumer-directed benefits ("CDBs"), today announced financial results for its second quarter ended July 31, 2026.

"HealthEquity delivered a record-setting second quarter, with record Adjusted EBITDA margin of 48%, record HSA accounts of 10.7 million and record HSA Assets of nearly $38 billion," said Scott Cutler, President and CEO of HealthEquity. "These results reflect strong execution across the business and the durability of our model as growth comes from more places, member relationships deepen and technology-enabled efficiency improves how we serve members and clients. This momentum gives us confidence to raise fiscal 2027 guidance and enter the second half focused on scaling efficiently and creating long-term value."

Second quarter financial results

Revenue for the second quarter ended July 31, 2026 was $350.7 million, an increase of 8% compared to $325.8 million for the second quarter ended July 31, 2025. Revenue this quarter included: service revenue of $124.4 million, custodial revenue of $175.9 million, and interchange revenue of $50.4 million.

Net income was $65.6 million, or $0.78 per diluted share, for the second quarter ended July 31, 2026, compared to $59.9 million, or $0.68 per diluted share, for the second quarter ended July 31, 2025. Net income margin was 19% for the second quarter ended July 31, 2026, compared to 18% for the second quarter ended July 31, 2025.

Non-GAAP net income was $103.8 million, or $1.24 per diluted share, for the second quarter ended July 31, 2026, compared to $94.6 million, or $1.08 per diluted share, for the second quarter ended July 31, 2025.

Adjusted EBITDA was $167.0 million for the second quarter ended July 31, 2026, an increase of 11% compared to the second quarter ended July 31, 2025. Adjusted EBITDA was 48% of revenue, compared to 46% for the second quarter ended July 31, 2025.

Account and asset metrics

New HSAs from sales were 202 thousand, an increase of 24% compared to the second quarter ended July 31, 2025. HSAs as of July 31, 2026 were 10.7 million, an increase of 8% year over year, including 0.9 million HSAs with investments, an increase of 20% year over year. Total Accounts as of July 31, 2026 were 17.8 million, including 7.0 million complementary CDBs.

Total HSA Assets as of July 31, 2026 were $37.9 billion, an increase of 14% year over year. Total HSA Assets included $17.4 billion of HSA cash and $20.6 billion of HSA investments. Client-held funds, which are deposits held on behalf of our Clients to facilitate administration of our CDBs, and from which we generate custodial revenue, were $0.9 billion as of July 31, 2026.

Stock repurchase program

The Company repurchased 1.2 million shares of its common stock for $108.1 million during the second quarter ended July 31, 2026. As of July 31, 2026, $948.4 million of common stock remained authorized for repurchase under the stock repurchase program.

Business outlook

For the fiscal year ending January 31, 2027, management is raising guidance and now expects revenues of $1.411 billion to $1.421 billion. Its outlook for net income is between $242 million and $248 million, resulting in net income of $2.88 to $2.96 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $392 million and $398 million, resulting in non-GAAP net income per diluted share of $4.66 to $4.73 (based on an estimated 84 million diluted weighted-average shares outstanding). Management expects Adjusted EBITDA of $628 million to $636 million.

See “Non-GAAP financial information” below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.

Conference call

HealthEquity management will host a conference call at 8:30 a.m. (Eastern Time) on Thursday, August 27, 2026 to discuss the fiscal 2027 second quarter financial results. The conference call will be accessible by dialing 1-833-630-1956, or 1-412-317-1837 for international callers, and referencing conference ID "HealthEquity." A live audio webcast of the call will be available on the investor relations section of our website at http://ir.healthequity.com.

Non-GAAP financial information

To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.

Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.Non-GAAP net income is calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding. Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP financial measures, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.

About HealthEquity

HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for more than 17 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to save and improve lives by empowering healthcare consumers. For more information, visit www.healthequity.com.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.

Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:

our ability to adequately place and safeguard our custodial assets, or the failure of any of our depository or insurance company partners;our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;our dependence on the continued availability and benefits of tax-advantaged HSAs and other CDBs;the impact of fraudulent account activity involving our member accounts or our third-party service providers on our reputation and financial results;our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;the significant competition we face and may face in the future, including from those with greater resources than us;our reliance on the availability and performance of our technology and communications systems;potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;our reliance on partners and third-party vendors for distribution and important services;our ability to develop and implement updated features for our technology platforms and communications systems; andour reliance on our management team and key team members. For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2026 and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact
Richard Putnam
801-727-1000
[email protected]

HealthEquity, Inc. and subsidiaries
Condensed consolidated balance sheets
       (in thousands, except par value)July 31, 2026
  January 31, 2026
  (unaudited)
   Assets   Current assets   Cash and cash equivalents$                       256,003  $                       318,927 Accounts receivable, net of allowance for doubtful accounts of $1,067 and $924 as of July 31,
2026 and January 31, 2026, respectively                         122,193                           123,696 Prepaid expenses and other current assets                           82,008                             69,658 Total current assets                         460,204                           512,281 Property and equipment, net                             4,823                               3,177 Operating lease right-of-use assets                           32,874                             36,310 Intangible assets, net                      1,047,797                        1,097,172 Goodwill                       1,648,145                         1,648,145 Other assets                           77,520                             83,247 Total assets$                    3,271,363  $                    3,380,332 Liabilities and stockholders’ equity   Current liabilities   Accounts payable$                          8,592  $                        12,159 Accrued compensation                           37,913                             60,392 Accrued liabilities                           97,300                             74,388 Operating lease liabilities                             9,970                               9,911 Total current liabilities                          153,775                            156,850 Long-term liabilities   Long-term debt, net of issuance costs                          931,062                            957,379 Operating lease liabilities, non-current                           29,984                             34,190 Other long-term liabilities                           73,999                             31,007 Deferred tax liability                           92,433                             93,710 Total long-term liabilities                      1,127,478                        1,116,286 Total liabilities                      1,281,253                        1,273,136 Commitments and contingencies   Stockholders’ equity   Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and
outstanding as of July 31, 2026 and January 31, 2026, respectively                                   —                                     — Common stock, $0.0001 par value, 900,000 shares authorized, 82,909 and 85,007 shares
issued and outstanding as of July 31, 2026 and January 31, 2026, respectively                                    8                                      8 Additional paid-in capital                       1,896,571                         1,916,989 Accumulated earnings                         162,583                           195,906 Accumulated other comprehensive loss                          (69,052)                             (5,707)Total stockholders’ equity                      1,990,110                        2,107,196 Total liabilities and stockholders’ equity$                    3,271,363  $                    3,380,332  HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of operations (unaudited)    Three months ended July 31,
  Six months ended July 31,
 (in thousands, except per share data) 2026   2025   2026   2025 Revenue       Service revenue$              124,444  $              117,873  $              247,376  $              237,657 Custodial revenue                 175,936                   159,876                   350,270                   316,331 Interchange revenue                  50,352                    48,086                   107,727                   102,691 Total revenue                 350,732                   325,835                   705,373                   656,679 Cost of revenue       Service costs                  73,170                    75,156                   151,496                   163,161 Custodial costs                  12,083                    11,137                    23,738                    21,884 Interchange costs                    7,525                      6,947                    15,873                    14,728 Total cost of revenue                  92,778                    93,240                   191,107                   199,773 Gross profit                 257,954                   232,595                   514,266                   456,906 Operating expenses       Sales and marketing                  23,215                    19,922                    50,048                    45,906 Technology and development                  73,923                    64,804                   141,690                   126,240 General and administrative                  34,869                    29,990                    66,000                    55,526 Amortization of acquired intangible assets                  26,286                    27,001                    52,801                    54,003 Merger integration                       971                      1,266                      2,084                      2,541 Total operating expenses                 159,264                   142,983                   312,623                   284,216 Income from operations                  98,690                    89,612                   201,643                   172,690 Other expense       Interest expense                 (12,605)                  (14,955)                  (25,193)                  (29,813)Other income, net                    1,780                      3,391                      3,828                      6,124 Total other expense                 (10,825)                  (11,564)                  (21,365)                  (23,689)Income before income taxes                  87,865                    78,048                   180,278                   149,001 Income tax provision                  22,221                    18,194                    45,216                    35,232 Net income$               65,644  $               59,854  $              135,062  $              113,769 Net income per share:       Basic$                   0.79  $                   0.69  $                   1.61  $                   1.31 Diluted$                   0.78  $                   0.68  $                   1.60  $                   1.29 Weighted-average number of shares used in computing net income per share:       Basic                  83,374                    86,550                    83,885                    86,601 Diluted                  84,014                    87,746                    84,578                    88,153  HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of comprehensive income (unaudited)    Three months ended July 31, Six months ended July 31,(in thousands) 2026   2025  2026   2025Net income$               65,644  $               59,854 $              135,062  $              113,769Other comprehensive income (loss)       Cash flow hedges       Net unrealized gains (losses)                 (37,322)                        203                  (63,219)                        203Reclassification of net (gains) losses included in net income                         22                            —                       (126)                           —Net change, net of income tax benefit (expense) of $12,135, $(70), $20,598, and $(70), respectively                 (37,300)                        203                  (63,345)                        203Total other comprehensive income (loss)                 (37,300)                        203                  (63,345)                        203Comprehensive income$               28,344  $               60,057 $               71,717  $              113,972 HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited)   Six months ended July 31,
 (in thousands) 2026   2025 Cash flows from operating activities:   Net income$                       135,062  $                       113,769 Adjustments to reconcile net income to net cash provided by operating activities:   Depreciation and amortization                           80,169                             77,195 Stock-based compensation                           41,616                             33,404 Amortization of debt discount and issuance costs                                558                                  533 Amortization of gains on derivatives                               (168)                                    — Deferred taxes                           19,321                             30,711 Changes in operating assets and liabilities:   Accounts receivable, net                             1,503                               6,842 Prepaid expenses and other current and non-current assets                          (12,581)                           (20,650)Operating lease right-of-use assets                             3,436                               3,339 Accrued compensation                          (21,095)                           (35,032)Accounts payable, accrued liabilities, and other current liabilities                          (13,595)                             (3,785)Operating lease liabilities, non-current                            (4,206)                             (3,951)Other long-term liabilities                             3,665                              (1,771)Net cash provided by operating activities                          233,685                            200,604 Cash flows from investing activities:   Capitalized software development costs                          (30,720)                           (26,464)Purchases of property and equipment                            (1,340)                                (859)Settlement of derivatives, net                            (7,759)                                    — Net cash used in investing activities                          (39,819)                           (27,323)Cash flows from financing activities:   Repurchases of common stock                        (231,054)                         (125,810)Principal payments on long-term debt                          (26,875)                           (50,000)Settlement of client-held funds obligation, net                                480                                  596 Proceeds from exercise of common stock options                                659                             10,446 Net cash used in financing activities                        (256,790)                         (164,768)Increase (decrease) in cash and cash equivalents                          (62,924)                              8,513 Beginning cash and cash equivalents                          318,927                            295,948 Ending cash and cash equivalents$                       256,003  $                       304,461  HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited) (continued)  Six months ended July 31,(in thousands) 2026  2025Supplemental cash flow data:   Interest expense paid in cash$                        23,350 $                        28,362Income tax payments, net                           35,586                              6,507Supplemental disclosures of non-cash investing and financing activities:   Capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation                             3,434                              3,380Purchases of property and equipment included in accounts payable or accrued liabilities                             1,294                                 155Repurchases of common stock included in accrued liabilities                             3,255                              1,246Exercise of common stock options receivable                                  57                                    — Stock-based compensation expense (unaudited)Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive income is as follows:

 Three months ended July 31, Six months ended July 31,(in thousands) 2026  2025  2026  2025Cost of revenue$                 2,713 $                 3,114 $                 5,500 $                 6,501Sales and marketing                    3,229                     1,529                     7,753                     6,399Technology and development                    6,178                     5,732                   10,131                   11,652General and administrative                  10,090                     8,693                   18,232                     8,852Total stock-based compensation expense$               22,210 $               19,068 $               41,616 $               33,404 Total Accounts (unaudited)       (in thousands, except percentages)July 31, 2026 July 31, 2025 % Change January 31, 2026HSAs                 10,739                    9,989 8 %
                  10,570New HSAs from sales - Quarter-to-date                      202                       163 24 %
                       553New HSAs from sales - Year-to-date                      374                       312 20 %
                    1,040New HSAs from acquisitions - Year-to-date                         —                          — *                          —HSAs with investments                      939                       782 20 %
                       832CDBs                   7,016                    7,153 (2)%                    7,221Total Accounts                 17,755                  17,142 4 %
                  17,791Average Total Accounts - Quarter-to-date                 17,710                  17,044 4 %
                  17,462Average Total Accounts - Year-to-date                 17,772                  17,083 4 %
                  17,220 *     Not meaningful

HSA Assets (unaudited)       (in millions, except percentages)July 31, 2026 July 31, 2025 % Change January 31, 2026HSA cash$               17,369 $               17,035 2%
 $               17,982HSA investments                  20,552                   16,102 28%
                   18,482Total HSA Assets                  37,921                   33,137 14%
                   36,464Average daily HSA cash - Quarter-to-date                  17,388                   17,017 2%
                   17,090Average daily HSA cash - Year-to-date                  17,547                   17,149 2%
                   17,082 HSA cash maturity scheduleThe following table summarizes the amount of HSA cash held by our depository partners and insurance company partners that is expected to reprice by fiscal year and the respective average annualized yield currently earned on that HSA cash as of July 31, 2026:

Year ending January 31, (in billions, except percentages)HSA cash expected to reprice Average annualized yieldRemainder of 2027$                              2.3 1.5%
2028                                 2.5 4.0%
2029                                 1.8 3.8%
2030                                 2.3 4.4%
Thereafter                                 7.8 4.4%
Total (1)$                            16.7 3.9%
(1)  Excludes $0.7 billion of HSA cash held in floating-rate contracts as of July 31, 2026.

Client-held funds (unaudited)       (in millions, except percentages)July 31, 2026 July 31, 2025 % Change January 31, 2026Client-held funds$                    931 $                    818 14 %
 $                 1,090Average daily Client-held funds - Quarter-to-date                       936                        884 6 %
                        879Average daily Client-held funds - Year-to-date                       986                        893 10 %
                        864 Reconciliation of net income to Adjusted EBITDA (unaudited)    Three months ended July 31,
  Six months ended July 31,
 (in thousands) 2026   2025   2026   2025 Net income$               65,644  $               59,854  $              135,062  $              113,769 Interest income                   (1,760)                    (3,364)                    (3,647)                    (6,097)Interest expense                  12,605                    14,955                    25,193                    29,813 Income tax provision                  22,221                    18,194                    45,216                    35,232 Depreciation and amortization                  15,669                    11,453                    27,368                    23,192 Amortization of acquired intangible assets                  26,286                    27,001                    52,801                    54,003 Stock-based compensation expense                  22,210                    19,068                    41,616                    33,404 Merger integration expenses                       971                      1,266                      2,084                      2,541 Amortization of incremental costs to obtain a contract                    2,139                      1,951                      4,255                      3,877 Costs associated with unused office space                    1,016                         723                      1,702                      1,575 Other                        (20)                         (27)                       (181)                         (27)Adjusted EBITDA$              166,981  $              151,074  $              331,469  $              291,282  Net income and Adjusted EBITDA as a percentage of revenue (unaudited) Three months ended July 31,     Six months ended July 31,    (in thousands, except
percentages) 2026   2025  $ Change % Change  2026   2025  $ Change % ChangeNet income$      65,644  $      59,854  $     5,790 10 % $    135,062  $    113,769  $   21,293 19 %As a percentage of revenue 19 %  18%      19 %  17 %    Adjusted EBITDA$    166,981  $    151,074  $   15,907 11  % $    331,469  $    291,282  $   40,187 14 %As a percentage of revenue 48 %  46%      47 %  44 %     Reconciliation of net income outlook to Adjusted EBITDA
(unaudited)  Outlook for the year ending(in millions)January 31, 2027Net income$242 - 248Interest income(7)
Interest expense50
Income tax provision81 - 83Depreciation and amortization54
Amortization of acquired intangible assets104
Stock-based compensation expense87
Merger integration expenses5
Amortization of incremental costs to obtain a contract9
Costs associated with unused office space3
Adjusted EBITDA$628 - 636 Note: Values presented may not calculate due to rounding.

Reconciliation of net income to non-GAAP net income (unaudited)

    Three months ended July 31, Six months ended July 31,(in thousands, except per share data) 2026  2025  2026  2025Net income$               65,644 $               59,854 $              135,062 $              113,769Income tax provision                  22,221                   18,194                   45,216                   35,232Income before income taxes - GAAP                  87,865                   78,048                  180,278                  149,001Non-GAAP adjustments:       Amortization of acquired intangible assets                  26,286                   27,001                   52,801                   54,003Stock-based compensation expense                  22,210                   19,068                   41,616                   33,404Merger integration expenses                       971                     1,266                     2,084                     2,541Costs associated with unused office space                    1,016                        723                     1,702                     1,575Total adjustments to income before income taxes - GAAP                  50,483                   48,058                   98,203                   91,523Income before income taxes - Non-GAAP                 138,348                  126,106                  278,481                  240,524Income tax provision - Non-GAAP (1)                  34,586                   31,526                   69,620                   60,130Non-GAAP net income                 103,762                   94,580                  208,861                  180,394        Diluted weighted-average shares                  84,014                   87,746                   84,578                   88,153GAAP net income per diluted share$                   0.78 $                   0.68 $                   1.60 $                   1.29Non-GAAP net income per diluted share$                   1.24 $                   1.08 $                   2.47 $                   2.05 (1)The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations. Reconciliation of net income outlook to non-GAAP net income outlook (unaudited)

  Outlook for the year ending(in millions, except per share data)January 31, 2027Net income$242 - 248Income tax provision81 - 83Income before income taxes - GAAP323 - 331Non-GAAP adjustments: Amortization of acquired intangible assets104Stock-based compensation expense87Merger integration expenses5Costs associated with unused office space3Total adjustments to income before income taxes - GAAP199Income before income taxes - Non-GAAP522 - 530Income tax provision - Non-GAAP (1)131 - 133Non-GAAP net income$392 - 398  Diluted weighted-average shares84GAAP net income per diluted share$2.88 - 2.96Non-GAAP net income per diluted share$4.66 - 4.73 Note: Values presented may not calculate due to rounding.

(1) The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations. Certain termsTermDefinitionHSAHealth Savings Account, which is a financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis.CDBConsumer-directed benefits offered by employers, including flexible spending and health reimbursement arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits.HSA memberConsumers with HSAs that we serve.Total HSA AssetsHSA members’ custodial cash assets held by our federally insured depository partners and our insurance company partners. Total HSA Assets also includes HSA members' investments held by our custodial investment fund partner.ClientOur employer clients.Total AccountsThe sum of HSAs and CDBs on our platforms.Client-held fundsDeposits held on behalf of our Clients to facilitate administration of our CDBs.Network PartnerOur health plan partners, benefits administrators, and retirement plan recordkeepers.Adjusted EBITDAEarnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.Non-GAAP net incomeCalculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.Non-GAAP net income per diluted shareCalculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.

Canada Pension Plan Investment Board purchased a new stake in HealthEquity, Inc. (NASDAQ:HQY – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 135,600 shares of the company’s stock, valued at approximately $12,247,000. Canada Pension Plan Investment Board owned 0.16% of HealthEquity as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Acumen Wealth Advisors LLC acquired a new stake in shares of HealthEquity during the 4th quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd lifted its position in shares of HealthEquity by 1,723.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $28,000 after acquiring an additional 293 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in shares of HealthEquity during the 4th quarter valued at $28,000. Leonteq Securities AG boosted its stake in HealthEquity by 159.9% during the first quarter. Leonteq Securities AG now owns 382 shares of the company’s stock worth $32,000 after acquiring an additional 235 shares in the last quarter. Finally, Axiom Investment Management LLC bought a new position in HealthEquity during the first quarter worth $33,000. 99.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In HQY has been the subject of several research analyst reports. Wells Fargo & Company set a $111.00 price target on shares of HealthEquity in a research note on Monday, June 1st. Citigroup reissued a “market outperform” rating on shares of HealthEquity in a research report on Friday. Weiss Ratings upgraded HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, June 5th. Royal Bank Of Canada raised their target price on HealthEquity from $100.00 to $108.00 and gave the company an “outperform” rating in a research note on Wednesday, June 3rd. Finally, Telsey Advisory Group set a $111.00 target price on HealthEquity in a research report on Friday. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $110.93.

Check Out Our Latest Analysis on HQY More HealthEquity News Here are the key news stories impacting HealthEquity this week:

Positive Sentiment: HealthEquity exceeded expectations with adjusted earnings of $1.24 per share versus the $1.19 consensus, while revenue reached $350.7 million, slightly above estimates. Revenue increased 95.5% year over year. HealthEquity Q2 Earnings and Revenues Top Estimates Positive Sentiment: Profitability improved, with net income rising 10% to $65.6 million and net margin expanding to 19% from 18%. Adjusted EBITDA grew 11% to $167 million, while its margin increased to 48% from 46%. HealthEquity Second-Quarter Financial Results Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $4.66–$4.73, above the $4.56 analyst consensus. Record HSA assets of $37.9 billion provide additional support for the company’s long-term growth outlook. HealthEquity Raises Fiscal 2027 Guidance Positive Sentiment: BTIG Research reaffirmed its “buy” rating and raised its price target to $115. Another analysis indicated that HQY could be approximately 19% undervalued after the guidance increase, reinforcing the bullish interpretation of the earnings update. BTIG Research Rating HealthEquity Could Be Undervalued Neutral Sentiment: Fiscal 2027 revenue guidance of approximately $1.4 billion was broadly in line with expectations, so the guidance improvement was driven mainly by stronger anticipated earnings and margins. Negative Sentiment: Director Adrian T. Dillon sold 7,632 shares valued at approximately $798,000, reducing his position by 10.9%. The sale was executed under a pre-arranged Rule 10b5-1 plan, which reduces its negative signaling value but could still attract investor attention. HealthEquity Director Stock Sale Negative Sentiment: HQY trades at a premium valuation of roughly 35 times earnings. After the recent advance toward its 52-week high, some investors may lock in gains, potentially tempering the stock’s reaction to otherwise favorable fundamentals. Insider Transactions at HealthEquity In other news, Director Adrian T. Dillon sold 7,632 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total value of $798,383.52. Following the completion of the sale, the director directly owned 62,395 shares of the company’s stock, valued at $6,527,140.95. This represents a 10.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Henry Fiore sold 2,470 shares of the stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $95.00, for a total value of $234,650.00. Following the completion of the sale, the executive vice president directly owned 56,643 shares of the company’s stock, valued at approximately $5,381,085. This trade represents a 4.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 12,456 shares of company stock valued at $1,256,664 in the last quarter. Company insiders own 1.60% of the company’s stock.

HealthEquity Stock Performance NASDAQ HQY opened at $96.37 on Friday. The company has a fifty day simple moving average of $98.16 and a 200 day simple moving average of $87.87. HealthEquity, Inc. has a 12-month low of $72.76 and a 12-month high of $107.62. The company has a current ratio of 2.99, a quick ratio of 3.44 and a debt-to-equity ratio of 0.47. The company has a market cap of $8.06 billion, a P/E ratio of 34.79, a PEG ratio of 1.62 and a beta of 0.21.

HealthEquity (NASDAQ:HQY – Get Free Report) last posted its earnings results on Thursday, August 27th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.19 by $0.05. HealthEquity had a net margin of 17.36% and a return on equity of 15.33%. The company had revenue of $350.73 million during the quarter, compared to the consensus estimate of $349.22 million. HealthEquity’s revenue was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. Sell-side analysts predict that HealthEquity, Inc. will post 3.92 earnings per share for the current fiscal year.

HealthEquity Company Profile (Free Report)

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.

Featured Stories Five stocks we like better than HealthEquity From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash Venture Into High-Volatility Corners of the Market With These 3 ETFs 3 Retail Stocks to Watch After a Big Consumer Earnings Week Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HealthEquity, Inc. (NASDAQ:HQY – Free Report).

Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.

An EV maker on the rebound, a Sun Belt landlord facing fresh headwinds, and a clinical-stage biotech sitting on pivotal pipeline data have all landed on analysts' radars this week for very different reasons.

Three distinct sectors are drawing fresh analyst attention this week, spanning apartment REITs, electric vehicles and clinical-stage biotech. TD Cowen upgraded Rivian Automotive (NASDAQ:RIVN | RIVN Price Prediction) to Buy from Hold and raised its price target to $20, citing a detailed demand analysis for the upcoming R2 SUV. Truist maintained its Buy rating on Mid-America Apartment Communities (NYSE:MAA) but trimmed its price target to $142 from $146, pointing to near-term job market headwinds. Meanwhile, RBC Capital nudged its price target on Design Therapeutics (NASDAQ:DSGN) to $14 from $13 on an Outperform rating, with key pipeline data expected in the second half of 2026.

Together, the moves reflect a market still weighing macro pressures against company-specific catalysts.

Ticker Company Name Firm Old Rating New Rating Old Target New Target One-Line Takeaway RIVN Rivian Automotive TD Cowen Hold Buy $17 $20 R2 demand potential and post-selloff valuation drive the upgrade MAA Mid-America Apartment Communities Truist Buy Buy $146 $142 Buy maintained but near-term labor market softness warrants caution DSGN Design Therapeutics RBC Capital Outperform Outperform $13 $14 Pipeline progress and H2 2026 data readouts underpin the raised target The Analyst’s Case Rivian: TD Cowen’s upgrade rests on a proprietary demand analysis for the R2 SUV, projecting full-scale annual volumes of 212,000 to 335,000 units — well above what the broader analyst community is currently modeling for 2027. With Rivian stock down roughly 17.18% year to date, TD Cowen characterized the selloff as creating an attractive risk/reward profile at current levels. First deliveries of the R2 are targeted for Q2 2026, which gives the upgrade a clear near-term catalyst to watch.

MAA: Truist kept its Buy rating intact but acknowledged that weaker-than-expected national job growth is likely to weigh on near-term apartment revenue in MAA’s Sun Belt markets. The long-term thesis remains: as new apartment supply slows, fundamentals should gradually recover. The trim from $146 to $142 reflects a more measured timeline for that recovery rather than a change in conviction on the underlying business.

Design Therapeutics: RBC Capital’s incremental target raise to $14 reflects continued confidence in the company’s GeneTAC small-molecule platform and execution on its pipeline. Two programs are on track for data readouts in H2 2026: DT-216p2 targeting Friedreich’s ataxia and DT-168 targeting Fuchs Endothelial Corneal Dystrophy. RBC Capital’s raised target reflects a view that the risk/reward profile has modestly improved as the company moves closer to those milestones.

Company Snapshot and Recent Performance Rivian traded around $16.08 on Wednesday, Aug. 26, sitting well below its 52-week high of $22.69 but comfortably above its 52-week low of $12.39. The company posted its first full-year positive gross profit in Q4 2025, generating $120 million in quarterly gross profit and $144 million for the full year.

MAA shares traded around $132.12 on Aug. 26, down more than 5% year to date and off 7.36% over the past year. In 2026, same-store NOI growth is expected in a range of -1.70% to +0.30% for the year. On the positive side, resident turnover hit a record low of 40.2%, and MAA pays an annual dividend of $6.12 per share, translating to a yield of roughly 4.56% at current prices.

Design Therapeutics trade around $15.64 on Aug. 26, up nearly 72% year to date and nearly triple where it traded a year ago, with a 189.19% one-year gain. The company remains pre-revenue. Cash and investments of $219.84 million provide a runway the company says extends into 2029.

Why the Move Matters Now The consensus analyst price target for MAA suggests the stock is modestly undervalued relative to where the analyst community collectively sees fair value. Truist’s revised $142 target is slightly below that consensus, reflecting a more cautious near-term view. The backdrop matters: the national unemployment rate ticked up to 4.4% as of February 2026, up from 4.3% in January, a trend that can soften household formation and apartment demand in the near term.

For Rivian, TD Cowen’s $20 target implies meaningful upside from the current price of $15.87, and the R2 launch timeline in Q2 2026 gives investors a concrete catalyst within months. The consensus analyst target for RIVN stands at $17.88, making TD Cowen’s $20 target one of the more bullish on the Street.

For Design Therapeutics, the analyst community is uniformly constructive: Five analysts rate the stock Buy or Strong Buy, with zero Holds, Sells or Strong Sells. The consensus

Key Risks to Watch MAA: If job growth continues to soften and new apartment supply takes longer than expected to normalize, same-store NOI could come in at the low end of guidance or below. The 2026 same-store NOI range of -1.70% to +0.30% already reflects this uncertainty. Rivian: The R2 launch is critical, but any production delays, weaker-than-expected consumer demand, or further erosion of EV tax incentives could undermine the upgrade thesis quickly. The company’s adjusted EBITDA guidance of -$2.10 billion to -$1.80 billion for 2026 underscores that profitability remains a multi-year journey. Design Therapeutics: Clinical-stage biotech carries binary risk by definition. Negative or inconclusive Phase 1/2 data for DT-216p2 in H2 2026 could sharply reset the stock’s valuation, regardless of the cash position or pipeline breadth. This is not personalized financial advice. 247wallst.com and its writers do not own the stocks mentioned. Always do your own due diligence before investing.

Contact [email protected] for any questions or corrections.

A month has gone by since the last earnings report for Mid-America Apartment Communities (MAA - Free Report) . Shares have lost about 3.4% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Mid-America Apartment Communities due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

Mid-America Apartment Q2 FFO Misses Estimates as Same-Store NOI FallsMid-America Apartment reported second-quarter 2026 core FFO per share of $2.08, missing the Zacks Consensus Estimate of $2.10. The metric declined 3.3% from the year-ago quarter.

Rental and other property revenues increased 1% year over year to $555.13 million but missed the consensus mark of $555.97 million.

Same-store NOI fell 1%, though blended lease-rate growth improved to 0.7% amid steady demand.

MAA's Same-Store Portfolio Remains Under PressureSame-store revenues declined 0.3% year over year, while property operating expenses increased 0.8%. The combination drove a 1% decrease in same-store NOI. Same-store NOI totaled $316.22 million, down from $319.50 million a year earlier.

Average effective rent per unit slipped 0.2% to $1,688. Average physical occupancy was 95.3%, reflecting continued pressure from elevated apartment deliveries across several of MAA’s Sunbelt markets.

Mid-America Apartment Sees Better Leasing TrendsLeasing indicators showed sequential improvement despite the decline in property-level earnings. Effective blended lease-rate growth reached 0.7%, improving 20 basis points year over year and 100 basis points from the first quarter.

Effective new-lease pricing declined 5.3%, but that marked a 170-basis-point sequential improvement. Renewal lease rates increased 5.2%, helping offset weaker pricing on new leases.

Resident turnover remained historically low at 39.6%. Move-outs associated with residents purchasing single-family homes represented only 10.9% during the quarter, supporting occupancy and renewal demand.

Mid-America Apartment Advances Development PipelineMAA ended the quarter with six development projects totaling 1,749 units. Expected development costs were $597.50 million, of which $360.36 million had been funded, leaving $237.14 million of expected spending.

The company completed MAA Plaza Midwood in Charlotte, NC, and began construction of a 263-unit community in Kansas City, MO. It also completed the initial lease-up of MAA Cathedral Arts in Dallas.

Five lease-up projects contained 1,759 units and were 74.4% occupied at quarter-end. Costs incurred on those communities totaled $623.74 million. Management expects four projects to stabilize during the second half of 2026.

Mid-America Apartment Maintains Balance Sheet CapacityMAA ended June with $882.8 million of combined cash and available borrowing capacity. Total debt was $5.69 billion, with an average effective interest rate of 3.9% and an average maturity of six years.

Fixed-rate borrowings represented 86.6% of total debt. Net debt to adjusted EBITDAre was 4.5X compared with 4.3X at the end of 2025.

During the quarter, MAA repurchased 0.4 million shares for $50 million. The company also entered into a delayed-draw term loan with commitments of up to $350 million and had $100 million outstanding at quarter-end.

MAA Updates Its 2026 OutlookMAA narrowed its full-year core FFO guidance range to $8.41-$8.65 per share from $8.37-$8.69. The midpoint remained unchanged at $8.53.

The company reduced its same-store revenue growth outlook to a range of negative 0.2% to positive 0.4%, with a midpoint of 0.1%. Its same-store operating expense growth range was lowered to 1.25%-2.25%, while projected NOI growth was revised to negative 1.7% to negative 0.1%.

For the third quarter, MAA expects core FFO per share of $2.04-$2.16. The $2.10 midpoint reflects anticipated contributions from same-store and non-same-store NOI, partly offset by higher interest expense.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates review.

VGM ScoresCurrently, Mid-America Apartment Communities has a poor Growth Score of F, however its Momentum Score is doing a lot better with a B. Charting a somewhat similar path, the stock was allocated a score of C on the value side, putting it in the middle 20% for value investors.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Mid-America Apartment Communities has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Total sales increased 11%, on top of 10% last yearComparable store sales increased 2%, on top of 5% last yearNet income was $184 million, and diluted EPS was $2.88Excluding tariff refunds and certain expenses associated with bankruptcy acquired leases:   Adjusted EPS increased 38% to $2.37, on top of a 39% increase last yearAdjusted EBIT margin increased 100 basis points versus last yearIncreasing full year Adjusted EPS guidance to $11.77 to $11.97 BURLINGTON, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Burlington Stores, Inc. (NYSE: BURL), a nationally recognized off-price retailer of high-quality, branded apparel, footwear, accessories, and merchandise for the home at everyday low prices, today announced its results for the second quarter ended August 1, 2026.

Michael O’Sullivan, CEO, stated, “We are pleased with our strong financial performance in the second quarter, Total sales grew 11% on top of a strong 10% increase last year. Comp store sales increased 2% on top of 5% last year, for a solid 7% two-year stack. Excluding the impact of tariff refunds, Adjusted EPS grew 38% versus the second quarter of last year, on top of a 39% increase in the prior year. This was driven by a 100 basis point increase in our operating margin. This represented our 15th consecutive quarter of double digit EPS growth, reflecting our ability to consistently convert sales growth into margin expansion and exceptional earnings growth.”

Mr. O’Sullivan continued, “During the second quarter, we received $55 million in tariff refunds. Rather than taking a one-time boost to earnings, we intend to fully invest these refunds back into the business in the back-half of the year, to deliver even sharper values to our shoppers. Over the last few years, the rising cost of living has made life difficult for many customers. At Burlington, we already offer great deals. We plan to use the refunds to make these deals even better.”

Mr. O’Sullivan continued, “Given our intent to invest the refunds in sharper values, we expect the direct impact of tariff refunds to be neutral to full year earnings. That said, we are raising guidance for the full year, passing through our underlying performance beat from Q2. Our updated Fiscal 2026 guidance is for comp growth of 3% to 4% and EPS growth of 16% to 18%.”

Fiscal 2026 Second Quarter Operating Results 

Total sales increased 11% compared to the second quarter of Fiscal 2025 to $2,998 million, while comparable store sales increased 2% compared to the second quarter of Fiscal 2025. Gross margin rate as a percentage of net sales was 46.2% vs. 43.7% for the second quarter of Fiscal 2025, an increase of 250 basis points. Excluding the benefit of $55 million in tariff refunds, merchandise margin expanded 70 basis points, while freight expense increased 10 basis points as a percentage of net sales.Product sourcing costs, which are included in selling, general and administrative expenses (SG&A), were $226 million vs. $209 million in the second quarter of Fiscal 2025. Product sourcing costs include the costs of processing goods through our supply chain and buying costs. SG&A was 34.0% as a percentage of net sales vs 35.2% in the second quarter of Fiscal 2025. Adjusted SG&A, excluding $4 million and $11 million of expenses, respectively, associated with bankruptcy acquired leases, was 26.2% as a percentage of net sales vs. 26.7% in the second quarter of Fiscal 2025. The effective tax rate was 23.9% vs. 26.0% in the second quarter of Fiscal 2025. The Adjusted Effective Tax Rate was 23.6% vs. 26.0% in the second quarter of Fiscal 2025.Net income was $184 million, or $2.88 per share vs. $94 million, or $1.47 per share for the second quarter of Fiscal 2025. Adjusted Net Income, excluding the $41 million after tax benefit of tariff refunds, was $151 million, or $2.37 per share, vs. $110 million, or $1.72 per share for the second quarter of Fiscal 2025; this also excluded $3 million and $8 million, respectively, of expenses in each period, net of tax, associated with bankruptcy acquired leases.  Diluted weighted average shares outstanding amounted to 63.9 million during the quarter compared with 63.9 million during the second quarter of Fiscal 2025. Adjusted EBITDA was $324 million vs. $257 million in the second quarter of Fiscal 2025, which excludes the $55 million benefit of tariff refunds, as well as $4 million and $11 million, respectively, of expenses associated with bankruptcy acquired leases, an increase of 130 basis points as a percentage of sales. Adjusted EBIT was $210 million vs. $162 million in the second quarter of Fiscal 2025, excluding the same amounts, an increase of 100 basis points as a percentage of sales. First Six Months of Fiscal 2026 Results

Total sales increased 12% compared to the first six months of Fiscal 2025. Net income increased 53% compared to the same period in Fiscal 2025 to $299 million, or $4.67 per share vs. $3.05 per share in the prior period. Adjusted EBIT, excluding $12 million and $17 million, respectively, of expenses associated with bankruptcy acquired leases, as well as the $55 million benefit of tariff refunds, was $389 million vs. $314 million in the first six months of Fiscal 2025, an increase of 60 basis points as a percentage of sales. Adjusted Net Income, excluding $9 million and $12 million, respectively, of after-tax expenses associated with bankruptcy acquired leases, as well as the $41 million after-tax benefit of tariff refunds, was $286 million, or $4.46 per share, vs. $217 million, or $3.39 per share for the first six months of Fiscal 2025. Inventory

Merchandise inventories were $1,541 million vs. $1,415 million at the end of the second quarter of Fiscal 2025, a 9% increase, driven by our 149 net new stores and a comparable store inventory increase of 11% compared to the second quarter of Fiscal 2025. Reserve inventory was 43% of total inventory at the end of the second quarter of Fiscal 2026 compared to 50% at the end of the second quarter of Fiscal 2025. Reserve inventory is largely composed of merchandise that is purchased opportunistically and will be sent to stores in future months or next season.  Liquidity and Debt

The Company ended the second quarter of Fiscal 2026 with $1,646 million in liquidity, comprised of $704 million in unrestricted cash and $942 million in availability on its ABL facility.The Company ended the second quarter with $1,914 million in outstanding total debt, including $1,712 million on its Term Loan facility, $186 million in Convertible Notes, and no borrowings on its ABL facility. Common Stock Repurchases

During the second quarter of Fiscal 2026, the Company repurchased 270,279 shares of its common stock under its share repurchase program for $87 million. As of the end of the second quarter of Fiscal 2026, the Company had $218 million remaining on its current share repurchase program authorization. Outlook

Please note that guidance now includes the benefit of $55 million in tariff refunds, which were recognized in the second quarter of fiscal 2026. In addition, guidance also includes the reinvestment of approximately 40% of such refunds in the third quarter and approximately 60% in the fourth quarter of fiscal 2026. Tariff refunds therefore have a neutral impact on full fiscal year 2026 earnings guidance.

Excluding the $55 million planned tariff refund reinvestment, our underlying Fall guidance assumptions for EBIT margin improvement and earnings growth are unchanged versus prior guidance, estimated EBIT margin improvement of 10 to 30 basis points and EPS growth of 7% to 10%. As we noted earlier, we believe it is important to pass on those savings to our customers and drive even stronger value offerings.

For Fiscal Year 2026 (the 52-weeks ending January 30, 2027), the Company now expects:

Total sales to increase in the range of 10% to 11% on top of the 9% increase during Fiscal 2025; this assumes comparable store sales will increase in the range of 3% to 4%, on top of the 2% increase during Fiscal 2025; Capital expenditures, net of landlord allowances, to be approximately $875 million. This excludes any potential costs related to the relocation of our corporate headquarters, which is currently being evaluated. The timing and amount of such relocation expenditures are still uncertain;To open approximately 115 net new stores;  Depreciation and amortization to be approximately $460 million;  Adjusted EBIT margin to increase in the range of 20 to 40 basis points versus Fiscal 2025; excluding $16 million of anticipated expenses associated with bankruptcy acquired leases in Fiscal 2026 and $35 million in Fiscal 2025; Net interest expense to be approximately $55 million;  An Adjusted Effective Tax Rate of approximately 25%; and Adjusted EPS in the range of $11.77 to $11.97, as compared to $10.17 of Adjusted EPS last year; excluding $12 million, net of tax, of anticipated expenses associated with bankruptcy acquired leases in Fiscal 2026 and $26 million in Fiscal 2025. This assumes a fully diluted share count of approximately 64 million shares.  For the third quarter of Fiscal 2026 (the 13-weeks ending October 31, 2026), the Company expects:

Total sales to increase in the range of 9% to 11%; this assumes comparable store sales will increase in the range of 1% to 3% versus the third quarter of Fiscal 2025; Adjusted EBIT margin to decrease 80 to 60 basis points versus the third quarter of Fiscal 2025; excluding approximately $2 million of anticipated expenses associated with bankruptcy acquired leases in the third quarter of Fiscal 2026 and $11 million in the third quarter of Fiscal 2025; An Adjusted Effective Tax Rate of approximately 26%; and  Adjusted EPS in the range of $1.60 to $1.70, as compared to $1.80 in Adjusted EPS last year; excluding $2 million, net of tax, of anticipated expenses associated with bankruptcy acquired leases in the third quarter of Fiscal 2026 and $8 million in the third quarter of Fiscal 2025.  The Company has not provided a quantitative reconciliation of the forward-looking non-GAAP financial measures presented above to the comparable GAAP measures, because doing so would require estimates for items that are inherently difficult to predict and would involve unreasonable effort. These items may include, among others, costs related to debt amendments, losses on debt extinguishment, impairment charges, and the related tax effects. Some of these items could be significant. 

Note Regarding Non-GAAP Financial Measures

The foregoing discussion of the Company’s operating results includes references to Adjusted SG&A, Adjusted EBITDA, Adjusted Net Income, Adjusted Earnings per Share (or Adjusted EPS), Adjusted EBIT (or Adjusted EBIT Margin), and Adjusted Effective Tax Rate. The Company believes these supplemental measures are useful in evaluating the performance of our business and provide greater transparency into our results of operations. In particular, we believe that excluding certain items that may vary substantially in frequency and magnitude from what we consider to be our core operating results are useful supplemental measures that assist investors and management in evaluating our ability to generate earnings and leverage sales, and to more readily compare core operating results between past and future periods. These non-GAAP financial measures are defined and reconciled to the most comparable GAAP measures later in this document.    

Second Quarter 2026 Conference Call

The Company will hold a conference call on August 27, 2026 at 8:30 a.m. ET to discuss the Company’s second quarter results. The U.S. toll free dial-in for the conference call is 1-800-715-9871 (passcode: 3814903) and the international dial-in number is 1-646-307-1963. A live webcast of the conference call will also be available on the investor relations page of the company's website at www.burlingtoninvestors.com.

For those unable to participate in the conference call, a replay will be available after the conclusion of the call on August 27, 2026 beginning at 11:30 a.m. ET through September 3, 2026 11:59 p.m. ET. The U.S. toll-free replay dial-in number is 1-800-770-2030 and the international replay dial-in number is 1-609-800-9909. The replay passcode is 3814903.

About Burlington Stores, Inc.

Burlington Stores, Inc., headquartered in New Jersey, is a nationally recognized off-price retailer with Fiscal 2025 net sales of $11.5 billion. The Company is a Fortune 500 company and its common stock is traded on the New York Stock Exchange under the ticker symbol “BURL.” The Company operated 1,287 stores as of the end of the second quarter of Fiscal 2026 in 47 states, Washington D.C. and Puerto Rico, principally under the name Burlington Stores. The Company’s stores offer an extensive selection of in-season, high-quality branded merchandise at up to 60% off other retailers' prices, including fashion-focused women’s apparel, menswear, youth apparel, baby, beauty, footwear, accessories, home, toys, gifts and coats.  

For more information about the Company, visit www.burlington.com.

Investor Relations Contacts:
David J. Glick
Marisa Sharkey
855-973-8445
[email protected] 

Allison Malkin
ICR, Inc.
203-682-8225

Safe Harbor for Forward-Looking and Cautionary Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included in this release, including those about the external environment, as well as statements describing our outlook for future periods, are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. We do not undertake to publicly update or revise our forward-looking statements, except as required by law, even if experience or future changes make it clear that any projected results expressed or implied in such statements will not be realized. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual events or results to differ materially from those we expected, including general economic conditions, such as inflation, and the domestic and international political situation and the related impact on consumer confidence and spending; competitive factors, including the scale and potential consolidation of some of our competitors, rise of e-commerce spending, pricing and promotional activities of major competitors, and an increase in competition within the markets in which we compete; seasonal fluctuations in our net sales, operating income and inventory levels; the reduction in traffic to, or the closing of, the other destination retailers in the shopping areas where our stores are located; our ability to identify changing consumer preferences and demand; our ability to meet evolving regulatory requirements and stakeholder expectations regarding environmental, social or governance matters; extreme and/or unseasonable weather conditions caused by climate change or otherwise adversely impacting demand; effects of public health crises, epidemics or pandemics; our ability to sustain our growth plans or successfully implement our long-range strategic plans; our ability to execute our opportunistic buying and inventory management process; our ability to optimize our existing stores or maintain favorable lease terms; the availability, selection and purchasing of attractive brand name merchandise on favorable terms; our ability to attract, train and retain quality employees and temporary personnel in sufficient numbers; labor costs and our ability to manage a large workforce; the solvency of parties with whom we do business and their willingness to perform their obligations to us; import risks, including tax and trade policies, tariffs and government regulations; disruption in our distribution network; our ability to protect our information systems against service interruption, misappropriation of data, breaches of security, or other cyber-related attacks; risks related to the methods of payment we accept; the success of our advertising and marketing programs in generating sufficient levels of customer traffic and awareness; damage to our corporate reputation or brand; impact of potential loss of executives or other key personnel; our ability to comply with existing and changing laws, rules, regulations and local codes; lack of or insufficient insurance coverage; issues with merchandise safety and shrinkage; our ability to comply with increasingly rigorous privacy and data security regulations; impact of legal and regulatory proceedings relating to us; use of social media by us or by third parties at our direction in violation of applicable laws and regulations; our ability to generate sufficient cash to fund our operations and service our debt obligations; our ability to comply with covenants in our debt agreements; the consequences of the possible conversion of our convertible notes; our reliance on dividends, distributions and other payments, advance and transfers of funds from our subsidiaries to meet our obligations; the volatility of our stock price; the impact of the anti-takeover provisions in our governing documents; impact of potential shareholder activism; and each of the factors that may be described from time to time in our filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in our most recent Annual Report on Form 10-K. For each of these factors, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, as amended.

 BURLINGTON STORES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
(All amounts in thousands, except per share data)  Three Months Ended Six Months Ended  August 1, August 2, August 1, August 2,  2026 2025 2026 2025 REVENUES:        Net sales$2,997,778 $2,701,026 $5,850,088 $5,201,101 Other revenue 4,485  4,045  8,636  7,991 Total revenue 3,002,263  2,705,071  5,858,724  5,209,092 COSTS AND EXPENSES:        Cost of sales 1,614,011  1,519,629  3,208,815  2,924,720 Selling, general and administrative expenses 1,019,173  949,931  2,008,547  1,817,989 Costs related to debt amendments and inducement charges — —  15,315  112 Depreciation and amortization 114,022  94,810  218,630  186,593 Impairment charges - long-lived assets 3,577  1,580  4,385  2,095 Other income - net (4,156) (1,506) (5,607) (7,016)Interest income (6,140) (4,124) (12,301) (8,834)Interest expense 19,659  17,427  36,154  33,237 Total costs and expenses 2,760,146  2,577,747  5,473,938  4,948,896 Income before income tax expense 242,117  127,324  384,786  260,196 Income tax expense 57,813  33,139  85,738  65,178 Net income$184,304 $94,185 $299,048 $195,018          Diluted net income per common share$2.88 $1.47 $4.67 $3.05          Weighted average common shares - diluted 63,896  63,893  64,022  63,966   BURLINGTON STORES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(All amounts in thousands)  August 1, January 31, August 2,  2026 2026 2025 ASSETS      Current assets:      Cash and cash equivalents$703,686 $1,232,525 $747,619 Accounts receivable—net 128,087  105,296  111,236 Merchandise inventories 1,541,344  1,311,903  1,414,814 Assets held for disposal 2,579  3,364  417 Prepaid and other current assets 214,546  118,444  299,960 Total current assets 2,590,242  2,771,532  2,574,046 Property and equipment—net 3,389,646  3,164,218  2,836,035 Operating lease assets 3,674,007  3,624,786  3,542,956 Goodwill and intangible assets—net 285,064  285,064  285,064 Deferred tax assets 2,139  2,139  2,248 Other assets 102,757  71,318  68,914 Total assets$10,043,855 $9,919,057 $9,309,263 LIABILITIES AND STOCKHOLDERS' EQUITY      Current liabilities:      Accounts payable$1,108,717 $1,019,152 $1,024,320 Current operating lease liabilities 448,652  425,468  392,865 Other current liabilities 632,393  734,000  656,713 Current maturities of long term debt and other current debt 20,144  70,591  19,896 Total current liabilities 2,209,906  2,249,211  2,093,794 Long term debt 1,893,411  2,011,735  2,019,409 Long term operating lease liabilities 3,543,910  3,497,343  3,406,543 Other liabilities 74,723  75,738  77,097 Deferred tax liabilities 319,657  277,771  265,603 Stockholders' equity 2,002,248  1,807,259  1,446,817 Total liabilities and stockholders' equity$10,043,855 $9,919,057 $9,309,263   BURLINGTON STORES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(All amounts in thousands)
  Six Months Ended  August 1, August 2,  2026 2025 OPERATING ACTIVITIES    Net income$299,048 $195,018 Adjustments to reconcile net income to net cash provided by operating activities        Depreciation and amortization 218,630  186,593 Deferred income taxes 35,564  15,671 Non-cash stock compensation expense 68,416  54,264 Non-cash lease expense (4,917) (2,534)Cash received from landlord allowances 28,257  13,570 Inducement charges 15,315  — Changes in assets and liabilities:    Accounts receivable (23,989) (23,343)Merchandise inventories (229,441) (164,039)Accounts payable 95,486  (17,276)Other current assets and liabilities (177,653) (103,754)Other long term assets and liabilities 2,277  (1,981)Other operating activities 7,631  (1,657)Net cash provided by operating activities 334,624  150,532 INVESTING ACTIVITIES    Cash paid for property and equipment (532,384) (589,241)Lease acquisition costs (5,126) (19,942)Net (removal costs) proceeds from sale of property and equipment and assets held for sale (204) 27,769 Net cash used in investing activities (537,714) (581,414)FINANCING ACTIVITIES    Proceeds from long term debt—ABL Line of Credit —  150,000 Principal payments on long term debt—ABL Line of Credit —  (150,000)Proceeds from long term debt—Term Loan Facility —  495,000 Principal payments on long term debt—Term Loan Facility (8,763) (7,506)Principal payment on long term debt— Convertible Notes (128,638) (156,158)Purchase of treasury shares (222,295) (154,883)Other financing activities 33,947  7,350 Net cash (used in) provided by financing activities (325,749) 183,803 Decrease in cash and cash equivalents (528,839) (247,079)Cash and cash equivalents at beginning of period 1,232,525  994,698 Cash and cash equivalents at end of period$703,686 $747,619   Reconciliation of Non-GAAP Financial Measures
(Unaudited)
(Amounts in thousands, except per share data)
  The following tables calculate the Company’s Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBIT, Adjusted SG&A and Adjusted Effective Tax Rate, all of which are considered non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.

Adjusted Net Income is defined as net income, exclusive of the following items, if applicable: (i) net favorable lease costs; (ii) costs related to debt amendments and inducement charges; (iii) impairment charges; (iv) amounts related to certain litigation matters; and (v) other unusual or non-recurring expenses, losses, charges or gains, all of which are tax effected to arrive at Adjusted Net Income.

Adjusted EPS is defined as Adjusted Net Income divided by the diluted weighted average shares outstanding, as defined in the table below.

Adjusted EBITDA is defined as net income, exclusive of the following items, if applicable: (i) interest expense; (ii) interest income; (iii) costs related to debt amendments and inducement charges; (iv) income tax expense; (v) depreciation and amortization; (vi) net favorable lease costs (vii) impairment charges; (viii) amounts related to certain litigation matters; and (ix) other unusual or non-recurring expenses, losses, charges or gains.

Adjusted EBIT (or Adjusted Operating Income) is defined as net income, exclusive of the following items, if applicable: (i) interest expense; (ii) interest income; (iii) costs related to debt amendments and inducement charges; (iv) income tax expense; (v) impairment charges; (vi) net favorable lease costs; (vii) amounts related to certain litigation matters; and (viii) other unusual or non-recurring expenses, losses, charges or gains.

Adjusted EBIT Margin (or Adjusted Operating Margin) is defined as Adjusted EBIT divided by net sales.

Adjusted SG&A is defined as SG&A less product sourcing costs, favorable lease costs and amounts related to certain litigation matters.

Adjusted Effective Tax Rate is defined as the GAAP effective tax rate less the tax effect of the reconciling items to arrive at Adjusted Net Income (footnote (f) in the table below).

The Company presents Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBIT (or Adjusted Operating Income), Adjusted EBIT Margin (or Adjusted Operating Margin), Adjusted SG&A and Adjusted Effective Tax Rate, because it believes they are useful supplemental measures in evaluating the performance of the Company’s business and provide greater transparency into the results of operations. In particular, the Company believes that excluding certain items that may vary substantially in frequency and magnitude from what the Company considers to be its core operating results are useful supplemental measures that assist in evaluating the Company’s ability to generate earnings and leverage sales, and to more readily compare core operating results between past and future periods.

The Company believes that these non-GAAP measures provide investors helpful information with respect to the Company’s operations and financial condition. Other companies in the retail industry may calculate these non-GAAP measures differently such that the Company’s calculation may not be directly comparable.

The following table shows the Company’s reconciliation of net income to Adjusted Net Income and Adjusted EPS for the periods indicated:

 (unaudited) (in thousands, except per share data) Three Months Ended Six Months Ended August 1, August 2, August 1, August 2,  2026 2025 2026 2025 Reconciliation of net income to Adjusted Net Income:        Net income$184,304 $94,185 $299,048 $195,018 Net favorable lease costs (a) 2,047  1,932  3,849  4,070 Costs related to debt amendments and inducement charges (b) — —  15,315  112 Impairment charges - long-lived assets 3,577  1,580  4,385  2,095 Litigation matters (c) —  6,750  750  6,334 Tax effect (f) (655) (2,690) (5,179) (3,290)Adjusted Net Income$189,273 $101,757 $318,168 $204,339 Diluted weighted average shares outstanding (g) 63,896  63,893  64,022  63,966 Adjusted Earnings per Share$2.96 $1.59 $4.97 $3.19 
The following table shows the Company’s reconciliation of net income to Adjusted EBIT and Adjusted EBITDA for the periods indicated:

 (unaudited)  (in thousands)  Three Months EndedSix Months Ended  August 1, August 2, August 1, August 2,  2026 2025 2026 2025 Reconciliation of net income to Adjusted EBIT and Adjusted EBITDA:        Net income$184,304 $94,185 $299,048 $195,018 Interest expense 19,659  17,427  36,154  33,237 Interest income (6,140) (4,124) (12,301) (8,835)Net favorable lease costs (a) 2,047  1,932  3,849  4,070 Costs related to debt amendments and inducement charges (b) — —  15,315  112 Impairment charges - long-lived assets 3,577  1,580  4,385  2,095 Litigation matters (c) —  6,750  750  6,334 Income tax expense 57,813  33,139  85,738  65,178 Adjusted EBIT 261,260  150,889  432,938  297,209 Depreciation and amortization 114,022  94,810  218,630  186,593 Adjusted EBITDA$375,282 $245,699 $651,568 $483,802 
The following table shows the Company’s reconciliation of SG&A to Adjusted SG&A for the periods indicated:

 (unaudited)  (in thousands)  Three Months EndedSix Months Ended  August 1, August 2, August 1, August 2,  2026 2025 2026 2025 Reconciliation of SG&A to Adjusted SG&A:        SG&A$1,019,173 $949,931 $2,008,547 $1,817,989 Net favorable lease costs (a) (2,047) (1,932) (3,849) (4,070)Product sourcing costs (225,886) (208,982) (441,469) (405,829)Litigation matters (c) —  (6,750) (750) (6,334)Adjusted SG&A$791,240 $732,267 $1,562,479 $1,401,756 
The following table shows the reconciliation of the Company’s effective tax rates on a GAAP basis to the Adjusted Effective Tax Rates for the periods indicated:

 (unaudited)  Effective Tax Rates  Three Months Ended Six Months Ended  August 1, August 2, August 1, August 2,  2026 2025 2026 2025          Effective tax rate on a GAAP basis 23.9% 26.0% 22.3% 25.0%Adjustments to arrive at Adjusted Effective Tax Rate (h) (0.3) —  (0.1) 0.1 Adjusted Effective Tax Rate 23.6% 26.0% 22.2% 25.1%
The following table shows the Company’s reconciliation of net income to Adjusted Net Income for the prior period Adjusted EPS amounts used in this press release for the periods indicated:

 (unaudited)  (in thousands, except per share data)  Three Months Ended Fiscal Year Ended  November 1, 2025 January 31, 2026 Reconciliation of net income to Adjusted Net Income:    Net income$104,750 $610,153 Net favorable lease costs (a) 1,891  7,742 Costs related to debt amendments and inducement charges (b)—  112 Impairment charges 3,786  9,857 Litigation matters (c) (2,079) 4,175 Layaway liabilities (d) —  (12,716)Security tags (e) —  11,657 Tax effect (f) (890) (5,297)Adjusted Net Income$107,458 $625,683 Diluted weighted average shares outstanding (g) 64,068  64,126 Adjusted Earnings per Share$1.68 $9.76 
(a) Net favorable lease costs represent the non-cash expense associated with favorable and unfavorable leases that were recorded as a result of purchase accounting related to the April 13, 2006 Bain Capital acquisition of Burlington Coat Factory Warehouse Corporation. These expenses are recorded in the line item “Selling, general and administrative expenses” in our Condensed Consolidated Statements of Income.
(b) Fiscal 2026 amount represents an inducement charge related to the Company's exchange of certain of the 2027 Convertible Notes during the first quarter of Fiscal 2026. Fiscal 2025 amount relates to the settlement of the 2025 Convertible Notes during the first quarter of Fiscal 2025.
(c) Relates to the final settlements and amounts charged for certain litigation matters.
(d) Represents a one-time settlement of certain layaway liabilities on our Fiscal 2025 Consolidated Balance Sheet, resulting in a gain.
(e) Represents a one-time write-off to amortization related to certain merchandise security tags on our Fiscal 2025 Consolidated Balance Sheet.
(f) Tax effect is calculated based on the effective tax rates (before discrete items) for the respective periods, adjusted for the tax effect for the impact of items (a) through (e).
(g) Diluted weighted average shares outstanding starts with basic shares outstanding and adds back any potentially dilutive securities outstanding during the period.
(h) Adjustments for items excluded from Adjusted Net Income. These items have been described in the table above reconciling GAAP net income to Adjusted Net Income.

Bank of New York Mellon Corp bought a new stake in shares of Installed Building Products, Inc. (NYSE:IBP – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 164,338 shares of the construction company’s stock, valued at approximately $37,771,000. Bank of New York Mellon Corp owned about 0.61% of Installed Building Products as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. Danske Bank A S bought a new position in shares of Installed Building Products in the 3rd quarter valued at about $25,000. NewEdge Advisors LLC increased its stake in Installed Building Products by 5,000.0% during the third quarter. NewEdge Advisors LLC now owns 102 shares of the construction company’s stock worth $25,000 after acquiring an additional 100 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in Installed Building Products during the first quarter valued at approximately $30,000. Northwestern Mutual Wealth Management Co. raised its position in Installed Building Products by 700.0% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 152 shares of the construction company’s stock valued at $37,000 after purchasing an additional 133 shares during the period. Finally, Parallel Advisors LLC lifted its stake in shares of Installed Building Products by 446.7% in the 1st quarter. Parallel Advisors LLC now owns 164 shares of the construction company’s stock valued at $44,000 after purchasing an additional 134 shares during the last quarter. Institutional investors own 99.61% of the company’s stock.

Insider Buying and Selling at Installed Building Products In other news, CFO Michael Thomas Miller purchased 990 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $200.62 per share, with a total value of $198,613.80. Following the transaction, the chief financial officer owned 34,209 shares of the company’s stock, valued at $6,863,009.58. This represents a 2.98% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 13.80% of the company’s stock.

Analyst Ratings Changes A number of brokerages recently issued reports on IBP. Stephens lowered their price target on Installed Building Products from $300.00 to $240.00 and set an “equal weight” rating for the company in a research report on Friday, May 8th. Truist Financial reduced their target price on shares of Installed Building Products from $250.00 to $200.00 and set a “hold” rating on the stock in a research note on Friday, May 8th. Zacks Research upgraded shares of Installed Building Products from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. DA Davidson lifted their price target on shares of Installed Building Products from $242.00 to $250.00 and gave the stock a “neutral” rating in a research note on Monday, August 10th. Finally, Wells Fargo & Company dropped their price target on shares of Installed Building Products from $285.00 to $250.00 and set an “equal weight” rating for the company in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Installed Building Products currently has a consensus rating of “Hold” and an average price target of $249.30. Check Out Our Latest Stock Analysis on Installed Building Products

Installed Building Products Price Performance Shares of IBP stock opened at $246.12 on Friday. The company has a market capitalization of $6.54 billion, a P/E ratio of 26.49, a P/E/G ratio of 4.52 and a beta of 1.70. The company’s 50-day simple moving average is $232.34 and its two-hundred day simple moving average is $254.77. Installed Building Products, Inc. has a one year low of $193.11 and a one year high of $349.00. The company has a debt-to-equity ratio of 1.62, a current ratio of 2.98 and a quick ratio of 2.41.

Installed Building Products (NYSE:IBP – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The construction company reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.55 by $0.36. The firm had revenue of $777.80 million during the quarter, compared to the consensus estimate of $743.33 million. Installed Building Products had a net margin of 8.46% and a return on equity of 42.12%. The company’s revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.95 earnings per share. As a group, equities analysts anticipate that Installed Building Products, Inc. will post 9.82 EPS for the current year.

Installed Building Products Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Tuesday, September 15th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Tuesday, September 15th. Installed Building Products’s dividend payout ratio is currently 16.79%.

(Free Report)

Installed Building Products, Inc (NYSE: IBP) is a leading national installer of specialty building products serving the U.S. residential construction market. The company partners with homebuilders and contractors to deliver a comprehensive range of interior and exterior finishing services, including insulation, drywall finishing, protective coatings and basement waterproofing systems. By offering a single-source solution, Installed Building Products helps streamline project coordination and ensures consistent service quality across multiple trades.

Founded in 1977 and headquartered in Columbus, Ohio, Installed Building Products has expanded from a regional insulation installer into a nationwide platform operating in nearly every state.

Featured Articles Five stocks we like better than Installed Building Products 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude? Okta Stock Surges 29%—Is $200 the Next Stop? Want to see what other hedge funds are holding IBP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Installed Building Products, Inc. (NYSE:IBP – Free Report).

Receive News & Ratings for Installed Building Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Installed Building Products and related companies with MarketBeat.com's FREE daily email newsletter.

Bank of America Corp DE raised its position in Edgewell Personal Care Company (NYSE:EPC – Free Report) by 176.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 260,344 shares of the company’s stock after purchasing an additional 166,204 shares during the quarter. Bank of America Corp DE owned 0.56% of Edgewell Personal Care worth $5,556,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in EPC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Edgewell Personal Care by 3.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,564 shares of the company’s stock valued at $891,000 after buying an additional 931 shares during the period. Woodline Partners LP purchased a new position in Edgewell Personal Care during the 1st quarter valued at about $2,655,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Edgewell Personal Care by 16.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 117,127 shares of the company’s stock valued at $3,656,000 after acquiring an additional 16,285 shares in the last quarter. Jane Street Group LLC increased its stake in Edgewell Personal Care by 80.6% during the first quarter. Jane Street Group LLC now owns 81,179 shares of the company’s stock worth $2,534,000 after purchasing an additional 36,239 shares during the period. Finally, Norges Bank purchased a new stake in Edgewell Personal Care during the second quarter worth about $214,000. 91.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes Several research analysts have recently commented on EPC shares. Royal Bank Of Canada raised their price objective on shares of Edgewell Personal Care from $26.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Wells Fargo & Company increased their target price on shares of Edgewell Personal Care from $24.00 to $30.00 and gave the stock an “overweight” rating in a report on Wednesday, July 8th. UBS Group raised their price target on shares of Edgewell Personal Care from $29.00 to $32.00 and gave the company a “neutral” rating in a research report on Thursday, August 6th. Barclays boosted their price target on shares of Edgewell Personal Care from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Finally, Morgan Stanley set a $31.00 price objective on Edgewell Personal Care in a research report on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $31.83.

View Our Latest Analysis on EPC Edgewell Personal Care Trading Up 0.2% Shares of NYSE:EPC opened at $28.69 on Friday. Edgewell Personal Care Company has a 52 week low of $15.73 and a 52 week high of $29.95. The company’s 50 day moving average is $27.57 and its two-hundred day moving average is $23.18. The company has a market cap of $1.32 billion, a PE ratio of -14.35 and a beta of 0.39. The company has a current ratio of 1.84, a quick ratio of 1.12 and a debt-to-equity ratio of 0.85.

Edgewell Personal Care (NYSE:EPC – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.08. The business had revenue of $570.10 million during the quarter, compared to analysts’ expectations of $574.87 million. Edgewell Personal Care had a negative net margin of 4.55% and a positive return on equity of 5.76%. The company’s revenue for the quarter was down 9.1% on a year-over-year basis. During the same period in the previous year, the company earned $1.04 EPS. Edgewell Personal Care has set its FY 2026 guidance at 1.800-2.000 EPS. Equities analysts predict that Edgewell Personal Care Company will post 1.94 earnings per share for the current fiscal year.

Edgewell Personal Care Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 8th. Stockholders of record on Wednesday, September 9th will be issued a $0.15 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 2.1%. Edgewell Personal Care’s dividend payout ratio is presently -30.00%.

(Free Report)

Edgewell Personal Care Inc, incorporated in 2015 and headquartered in Shelton, Connecticut, is a global consumer products company specializing in personal care, sun care, shaving and feminine care solutions. The company emerged as a spin-off from Energizer Holdings’ personal care division, listing its shares on the New York Stock Exchange under the ticker “EPC.” Edgewell’s portfolio comprises well-known brands that cater to everyday personal grooming and protection needs.

In the shaving segment, Edgewell markets razors and refill blades under brands such as Schick and Wilkinson Sword, targeting both men’s and women’s grooming categories.

See Also Five stocks we like better than Edgewell Personal Care Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape SEC Probe Puts Wall Street Leverage Risk Back in Focus A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole Five Below’s Turnaround Is Working—But Has the Stock Run Too Far? Want to see what other hedge funds are holding EPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edgewell Personal Care Company (NYSE:EPC – Free Report).

Receive News & Ratings for Edgewell Personal Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewell Personal Care and related companies with MarketBeat.com's FREE daily email newsletter.

AWM Investment Company Inc. bought a new position in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 220,000 shares of the company’s stock, valued at approximately $6,343,000. AWM Investment Company Inc. owned about 0.29% of Progyny at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Progyny in the second quarter worth approximately $334,426,000. Wellington Management Group LLP raised its holdings in Progyny by 260.9% during the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after buying an additional 1,621,688 shares during the last quarter. Fort Washington Investment Advisors Inc. OH raised its holdings in Progyny by 46.9% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock valued at $45,734,000 after buying an additional 859,289 shares during the last quarter. Loomis Sayles & Co. L P purchased a new stake in Progyny during the 4th quarter valued at $19,917,000. Finally, William Blair Investment Management LLC purchased a new stake in Progyny during the 2nd quarter valued at $16,807,000. 94.93% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades Several equities analysts have recently commented on the stock. Citigroup reaffirmed an “outperform” rating on shares of Progyny in a research note on Monday, May 11th. Canaccord Genuity Group set a $35.00 price target on Progyny in a report on Friday, August 7th. Leerink Partners set a $38.00 price target on Progyny in a report on Wednesday, July 22nd. Zacks Research upgraded Progyny from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. Finally, Wells Fargo & Company assumed coverage on Progyny in a report on Thursday, August 20th. They issued an “overweight” rating and a $37.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.91.

Read Our Latest Research Report on PGNY Progyny Stock Up 1.5% Progyny stock opened at $25.82 on Wednesday. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $33.06. The company has a market capitalization of $1.98 billion, a P/E ratio of 28.07, a PEG ratio of 1.85 and a beta of 1.01. The stock’s 50 day moving average is $29.08 and its 200 day moving average is $23.55.

Progyny (NASDAQ:PGNY – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. The business had revenue of $350.51 million during the quarter, compared to analysts’ expectations of $349.05 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.19 earnings per share. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, equities analysts expect that Progyny, Inc. will post 1.19 EPS for the current year.

Progyny declared that its board has approved a stock repurchase plan on Tuesday, May 26th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to reacquire up to 10.3% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its shares are undervalued.

Insider Transactions at Progyny In other news, insider Geoffrey Clapp sold 1,530 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a total transaction of $39,137.40. Following the completion of the sale, the insider owned 59,117 shares of the company’s stock, valued at $1,512,212.86. The trade was a 2.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Mark S. Livingston sold 2,517 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $25.50, for a total value of $64,183.50. Following the completion of the sale, the chief financial officer owned 74,688 shares of the company’s stock, valued at approximately $1,904,544. The trade was a 3.26% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 13,563 shares of company stock valued at $351,968. 9.90% of the stock is owned by company insiders.

Progyny Profile (Free Report)

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.

Further Reading Five stocks we like better than Progyny Pathward’s Credit Scare Tests Its Comeback Story Wiring the AI Boom: Rumble’s $13.7B Pivot StoneX: Too Far Too Fast? DICK’s Sporting Goods Faces Pain Now for a Bigger Prize Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY – Free Report).

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.

Beacon Pointe Advisors LLC acquired a new stake in shares of Sprouts Farmers Market, Inc. (NASDAQ:SFM – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 108,818 shares of the company’s stock, valued at approximately $9,204,000. Beacon Pointe Advisors LLC owned 0.12% of Sprouts Farmers Market as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. TD Private Client Wealth LLC lifted its holdings in Sprouts Farmers Market by 1,309.1% during the fourth quarter. TD Private Client Wealth LLC now owns 310 shares of the company’s stock worth $25,000 after acquiring an additional 288 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Sprouts Farmers Market during the first quarter worth about $25,000. Newbridge Financial Services Group Inc. acquired a new stake in shares of Sprouts Farmers Market during the second quarter worth about $29,000. Bell Investment Advisors Inc bought a new position in shares of Sprouts Farmers Market during the 2nd quarter valued at about $29,000. Finally, Clearstead Advisors LLC lifted its holdings in shares of Sprouts Farmers Market by 72.7% during the 4th quarter. Clearstead Advisors LLC now owns 380 shares of the company’s stock valued at $30,000 after purchasing an additional 160 shares in the last quarter.

Sprouts Farmers Market Stock Up 0.5% SFM stock opened at $81.46 on Friday. Sprouts Farmers Market, Inc. has a twelve month low of $64.75 and a twelve month high of $141.78. The company has a market cap of $7.60 billion, a price-to-earnings ratio of 15.61, a P/E/G ratio of 2.01 and a beta of 0.68. The company has a quick ratio of 0.43, a current ratio of 0.99 and a debt-to-equity ratio of 0.07. The business has a 50 day moving average price of $81.82 and a two-hundred day moving average price of $79.55.

Sprouts Farmers Market (NASDAQ:SFM – Get Free Report) last issued its earnings results on Wednesday, July 29th. The company reported $1.37 EPS for the quarter, topping the consensus estimate of $1.35 by $0.02. Sprouts Farmers Market had a return on equity of 34.84% and a net margin of 5.58%.The company had revenue of $2.33 billion during the quarter, compared to the consensus estimate of $2.32 billion. During the same period in the previous year, the company posted $1.35 EPS. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. Sprouts Farmers Market has set its Q3 2026 guidance at 1.200-1.240 EPS and its FY 2026 guidance at 5.320-5.400 EPS. Analysts anticipate that Sprouts Farmers Market, Inc. will post 5.55 EPS for the current fiscal year. Insider Transactions at Sprouts Farmers Market In related news, Director Joseph D. O’leary sold 2,597 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $82.57, for a total transaction of $214,434.29. Following the completion of the sale, the director directly owned 14,710 shares in the company, valued at $1,214,604.70. This represents a 15.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Nicholas Konat sold 12,538 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $87.90, for a total transaction of $1,102,090.20. Following the completion of the sale, the chief operating officer owned 66,119 shares in the company, valued at approximately $5,811,860.10. The trade was a 15.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 58,289 shares of company stock valued at $4,991,405. 1.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes A number of analysts recently issued reports on SFM shares. Royal Bank Of Canada reissued an “outperform” rating and set a $114.00 target price on shares of Sprouts Farmers Market in a research note on Monday, June 1st. Evercore reaffirmed an “outperform” rating on shares of Sprouts Farmers Market in a research note on Monday, July 27th. Weiss Ratings reiterated a “hold (c)” rating on shares of Sprouts Farmers Market in a report on Wednesday, June 24th. JPMorgan Chase & Co. upgraded shares of Sprouts Farmers Market from a “neutral” rating to an “overweight” rating and upped their price target for the company from $80.00 to $103.00 in a report on Thursday, July 30th. Finally, Roth Capital set a $82.00 price objective on shares of Sprouts Farmers Market in a report on Friday, July 31st. Seven investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $91.58.

Get Our Latest Stock Analysis on Sprouts Farmers Market

(Free Report)

Sprouts Farmers Market, Inc (NASDAQ: SFM) is a specialty grocery retailer focused on fresh, natural and organic foods. Headquartered in Phoenix, Arizona, the company operates stores designed to offer an open-market shopping experience, emphasizing quality produce sourced from regional farmers alongside organic pantry staples, dairy, meat and seafood. Sprouts’ product assortment also includes bulk foods, vitamins and supplements, a deli and prepared foods, reflecting its commitment to wellness and affordable healthy living.

Founded in 2002 by members of the Boney family, Sprouts began as a single farmers market in Chandler, Arizona.

Read More Five stocks we like better than Sprouts Farmers Market 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude? Okta Stock Surges 29%—Is $200 the Next Stop?

Receive News & Ratings for Sprouts Farmers Market Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sprouts Farmers Market and related companies with MarketBeat.com's FREE daily email newsletter.

CHICAGO, /PRNewswire/ -- JLL Income Property Trust, an institutionally managed, daily NAV REIT (NASDAQ: ZIPTAX; ZIPTMX; ZIPIAX; ZIPIMX; ZIPIBX; ZIPSAX; ZIPZAX; ZIPDBX) with approximately $7 billion in portfolio equity and debt investments, announced the acquisition of Midtown Village, a retail shopping center in Tuscaloosa, Alabama for a purchase price of approximately $94 million.

The property is an open-air retail center totaling approximately 345,000 square feet and is leased to a mix of seasoned necessity anchor tenants as well as complementary apparel, food, and service tenants, with a weighted average lease term of 16+ years. The center is strategically located on the corner of Tuscaloosa's primary commercial intersection and is one of the most visited retail shopping centers in the state, with over 5.7 million annual visits. It is also located 1.5 miles from the University of Alabama's main campus and within one mile of DCH Regional Medical Center, Tuscaloosa's largest regional hospital, providing additional demand drivers.

"Midtown Village offers an attractive enhancement to our retail portfolio," said Allan Swaringen, President and CEO of JLL Income Property Trust. "The enduring demand of this strong tenant roster supports stable operating performance, and the center is well positioned in a thriving submarket with proven traffic. With retail construction and vacancies declining nationally, we anticipate this continued supply-demand imbalance to drive returns for the sector as a whole."

Retail real estate has been a mainstay in the JLL Income Property Trust portfolio since its inception in 2012. With the addition of this investment, grocery-anchored and necessity-driven retail investments comprise 13% of the total $7 billion portfolio, with approximately $900 million in assets across 22 open-air shopping centers.

JLL Income Property Trust is an institutionally managed, daily NAV REIT that owns a growing portfolio of real estate investments selected by an institutional investment management team and sponsored by one of the world's leading real estate services firms.

For more information on JLL Income Property Trust, please visit our website at www.jllipt.com.

JLL INCOME PROPERTY TRUST, INC. (NASDAQ: ZIPTAX; ZIPTMX; ZIPIAX; ZIPIMX; ZIPIBX; ZIPSAX; ZIPZAX; ZIPDBX),

JLL Income Property Trust, Inc. is a daily NAV REIT that owns and manages a diversified portfolio of high quality, income-producing residential, industrial, grocery-anchored retail, healthcare and office properties located in the United States. JLL Income Property Trust expects to further diversify its real estate portfolio over time, including on a global basis. For more information, visit www.jllipt.com.

ABOUT LASALLE INVESTMENT MANAGEMENT | INVESTING TODAY. FOR TOMORROW.

LaSalle Investment Management, a subsidiary of JLL, is a globally integrated, diverse real estate investment manager. On a global basis, LaSalle manages US$86.8 billion of assets in private and public real estate equity and debt investments as of Q1 2026. LaSalle's client base includes public and private pension funds, insurance companies, governments, corporations, endowments and private individuals from across the globe. LaSalle sponsors a diverse range of investment vehicles, including separate accounts, open- and closed-end funds, public securities and entity-level investments.

Forward Looking Statements and Future Results

This press release may contain forward-looking statements with respect to JLL Income Property Trust. Forward-looking statements are statements that are not descriptions of historical facts and include statements regarding management's intentions, beliefs, expectations, research, market analysis, plans or predictions of the future. Because such statements include risks, uncertainties and contingencies, actual results may differ materially from those expressed or implied by such forward-looking statements. Past performance is not indicative of future results and there can be no assurance that future dividends will be paid.

CONTACTS:

Michael Gelobter
LaSalle Investment Management
Email: [email protected]

Doug Allen
Dukas Linden Public Relations
Telephone: +1 646 722 6530
Email: [email protected]

SOURCE JLL Income Property Trust

Key Takeaways REYN expanded gross margin as manufacturing efficiency and pricing offset higher raw-material costs.Commodity headwinds have doubled to $400 million, increasing pressure on profitability and volumes.Cash flow and debt reduction support REYN, but pricing elasticity limits the case for aggressive entry. Reynolds Consumer Products Inc. (REYN - Free Report) is showing better profitability even as commodity inflation remains a major obstacle. Second-quarter 2026 gross margin expanded 180 basis points to 26%, while adjusted EBITDA rose 4.9% year over year to $171 million.

That improvement adds resilience, but it does not remove the central risk. Management now expects about $400 million of annualized commodity headwinds, up from the $200 million estimate cited in April.

Pricing and productivity are doing much of the heavy lifting. Second-quarter revenues increased 0.6% to $944 million and adjusted earnings rose 7.7% to 42 cents per share. Manufacturing efficiencies and supply-chain productivity helped gross profit advance 8.4% to $245 million despite higher raw-material costs.

The trade-off is visible in volumes. Retail volumes declined 5% in the quarter. Reynolds Cooking & Kitchen Essentials took 19 percentage points of pricing to offset commodity costs, while retail volumes fell 8%. Still, segment adjusted EBITDA increased 8.2% to $53 million.

Hefty Home & Tableware shows a similar margin-versus-volume pattern. Revenues fell 10.3% to $217 million and retail volumes dropped 14%, largely because of foam weakness. Adjusted EBITDA nevertheless increased 22.9% to $43 million as manufacturing productivity and lower promotional spending offset weaker volumes.

Hefty Storage & Organization offered a better demand signal. Revenues rose 5.4% to a second-quarter record of $176 million as retail volumes grew 8%. Hefty Waste & Clean-Up revenues slipped 1.3% to $233 million, but retail volumes were flat.

Peer results underscore the importance of cost control. Church & Dwight Co., Inc. (CHD - Free Report) reported second-quarter adjusted gross margin of 45.4%, up 40 basis points, with productivity helping offset inflation. The Clorox Company (CLX - Free Report) reported a 520-basis-point gross margin decline in its fiscal fourth quarter amid lower volume and higher commodity, manufacturing and logistics costs.

Reynolds also improved cash generation. Operating cash flow increased to $173 million in the first six months of 2026 from $147 million a year earlier. The company made a voluntary $50 million debt repayment, while net debt to trailing 12-month adjusted EBITDA remained at 2.1 times.

The outlook keeps the risk-reward balanced. Reynolds raised its 2026 net revenue outlook to growth of 1-3% but maintained adjusted earnings guidance of $1.57-$1.63 per share and adjusted EBITDA guidance of $660-$675 million. Third-quarter revenues are expected to be approximately flat year over year, with adjusted EBITDA projected at $160-$165 million versus $168 million a year earlier.

Valuation is not a major bargain relative to the peer group. REYN trades at 15.5X forward 12-month earnings, compared with 15.2X for the Zacks sub-industry. Its five-year median multiple is 16.9X.

Image Source: Zacks Investment Research

The bottom line is that better margins and productivity support the investment case, but commodity inflation, pricing elasticity and uneven category demand limit the argument for an aggressive entry. The company has protected profitability, yet the second-half setup still depends on pricing holding without causing too much volume pressure.

REYN currently carries a Zacks Rank #3 (Hold). It has a Value Score of B, Momentum Score of B and VGM Score of B, alongside a Growth Score of C. The B scores are relatively favorable, but the Zacks Rank #3 is not one of the top two ranks typically favored for new purchases. With current-year earnings estimates unchanged over the past four weeks, the stock looks better suited to a measured hold stance than a clear buy call at present.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

BlackRock Inc. bought a new stake in e.l.f. Beauty (NYSE:ELF – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,787,329 shares of the company’s stock, valued at approximately $428,262,000. BlackRock Inc. owned 9.82% of e.l.f. Beauty as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Deutsche Bank AG purchased a new position in e.l.f. Beauty in the second quarter worth about $3,365,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of e.l.f. Beauty during the 2nd quarter valued at about $2,375,000. Global Retirement Partners LLC purchased a new stake in shares of e.l.f. Beauty during the 2nd quarter valued at about $329,000. Bank of New York Mellon Corp bought a new position in shares of e.l.f. Beauty in the 2nd quarter worth approximately $23,624,000. Finally, State of Wyoming bought a new position in shares of e.l.f. Beauty in the 2nd quarter worth approximately $40,000. 92.44% of the stock is owned by hedge funds and other institutional investors.

Insider Activity In other news, Director Lauren Cooks Levitan sold 1,034 shares of e.l.f. Beauty stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $93.15, for a total transaction of $96,317.10. Following the sale, the director owned 10,516 shares in the company, valued at $979,565.40. This trade represents a 8.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Tarang Amin sold 50,164 shares of e.l.f. Beauty stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $78.24, for a total transaction of $3,924,831.36. Following the sale, the chief executive officer owned 110,496 shares in the company, valued at approximately $8,645,207.04. The trade was a 31.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 140,780 shares of company stock valued at $10,091,078 in the last three months. 3.50% of the stock is currently owned by insiders.

e.l.f. Beauty Stock Down 0.1% Shares of ELF stock opened at $105.90 on Wednesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.55 and a quick ratio of 1.82. e.l.f. Beauty has a one year low of $48.82 and a one year high of $150.99. The company’s fifty day moving average price is $81.10 and its 200-day moving average price is $72.39. The company has a market capitalization of $6.25 billion, a price-to-earnings ratio of 105.90, a PEG ratio of 3.29 and a beta of 1.58. e.l.f. Beauty (NYSE:ELF – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $1.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $1.04. The company had revenue of $479.37 million during the quarter, compared to the consensus estimate of $431.20 million. e.l.f. Beauty had a net margin of 3.38% and a return on equity of 14.07%. e.l.f. Beauty’s quarterly revenue was up 35.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.89 EPS. e.l.f. Beauty has set its FY 2027 guidance at 3.500-3.550 EPS. Sell-side analysts expect that e.l.f. Beauty will post 2.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In Several brokerages recently issued reports on ELF. Bank of America cut their target price on shares of e.l.f. Beauty from $93.00 to $85.00 and set a “buy” rating for the company in a research report on Thursday, May 21st. Canaccord Genuity Group increased their price target on shares of e.l.f. Beauty from $97.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, August 19th. Jefferies Financial Group lifted their price target on shares of e.l.f. Beauty from $72.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. UBS Group boosted their price objective on shares of e.l.f. Beauty from $80.00 to $89.00 and gave the company a “neutral” rating in a research report on Thursday, August 6th. Finally, Raymond James Financial upped their price objective on e.l.f. Beauty from $85.00 to $87.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, July 14th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.31.

Read Our Latest Report on ELF

About e.l.f. Beauty (Free Report)

e.l.f. Beauty (NYSE: ELF) is an American cosmetics company known for offering an extensive range of affordable, trend-driven makeup and skincare products. The company’s portfolio spans foundations, lipsticks, mascaras, brushes, serums, masks and other beauty essentials, all positioned at accessible price points. e.l.f. Beauty maintains a direct-to-consumer platform through its e-commerce site and engages in widespread retail partnerships with major chains such as Target, Walmart, Ulta Beauty and Amazon.

Founded in 2004 and headquartered in Oakland, California, e.l.f.

Further Reading Five stocks we like better than e.l.f. Beauty Pathward’s Credit Scare Tests Its Comeback Story Wiring the AI Boom: Rumble’s $13.7B Pivot StoneX: Too Far Too Fast? DICK’s Sporting Goods Faces Pain Now for a Bigger Prize Want to see what other hedge funds are holding ELF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for e.l.f. Beauty (NYSE:ELF – Free Report).

Receive News & Ratings for e.l.f. Beauty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for e.l.f. Beauty and related companies with MarketBeat.com's FREE daily email newsletter.

-

As burnout drives more physicians toward early retirement, many see AI fluency as their best shot at higher earnings

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced new data indicating that physicians are finding an unexpected source of optimism in AI. Rather than viewing the technology as a threat, nearly a quarter expect it to increase their total compensation within the next year, and two-thirds believe staying current with AI will give them a meaningful earnings edge over peers who don't.

The findings are part of Doximity’s annual Physician Compensation Report, which also shows that the physician shortage continues to weigh heavily on daily practice, with 76% of physicians saying it compromised the quality of care they were able to provide in the past year. That strain is showing up in a growing desire to leave medicine altogether as physicians report being overworked, considering a career change, or eyeing early retirement.

“Physicians go into medicine because they’re passionate about helping people,” said Amit Phull, MD, chief medical officer at Doximity. “Then the job compromises that mission. Admin burden. Extreme hours. A system that doesn’t feel built for them anymore. So it’s no surprise they're looking at AI as leverage, not a threat. Our job at Doximity is simple: give them time back through AI that helps them be more productive and provide better care for their patients.”

Report Highlights

Physicians See AI Fluency as the Next Career Advantage

Rather than fearing displacement, physicians are looking to capitalize: 23% expect AI to increase their total compensation within the next 12 months. 67% believe physicians who stay current with AI tools will have a meaningful earnings advantage over colleagues who don't adopt them in the next 12 months. AI Is the New Professional Currency

At least 39% of physicians surveyed said that AI proficiency is a factor in hiring and promotion decisions for their specialty, including 15% who described it as either a “major” or “moderate” factor. Shortage Still Straining Physicians Fuels Career-Exit Intent

85% of physicians said the physician shortage has already affected their clinical practice. 76% said the shortage and other systemic pressures compromised the quality of care they provided in the past 12 months. In a June 2026 Doximity poll of more than 600 physicians, 82% reported being overworked. Among overworked physicians, 66% are considering a career change, including 46% eyeing early retirement, up from 34%. Broader Compensation Trends

Average physician compensation rose 2% in 2025, down from 3.7% growth the year prior, continuing a trend of moderating pay growth. The gender pay gap held steady at 26% for the second consecutive year, with men earning a nominal $122,276 more than women on average. The pay gap between primary care physicians and specialists widened this year: surgical specialists now earn 90.1% more than primary care physicians, up from 87.3% in 2024. With over 85% of U.S. physicians as members, Doximity brings together one of the nation’s largest physician compensation datasets with workforce surveys, recruiting activity, staffing trends, and insights into AI adoption. The 2026 Physician Compensation Report features new survey findings from June 2026 on how AI is changing physician careers and pay, along with salary data from Doximity’s compensation dataset of more than 23,000 responses collected in 2025.

Read the full 2026 Physician Compensation Report here.

About Doximity

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. With new AI-powered clinical reference and search capabilities, Doximity also helps doctors access trusted, peer-reviewed information and medical literature. Doximity’s mission is to help doctors be more productive so they can provide better care for their patients.

More News From Doximity

Back to Newsroom

Urban Outfitters (NASDAQ:URBN) on Wednesday posted mixed results for the second quarter.

The company posted second-quarter adjusted earnings of $1.72 per share, missing market estimates of $1.73 per share. The company’s sales came in at $1.662 billion versus estimates of $1.635 billion.

“We are pleased to report our highest adjusted profit quarter in Company history, marking our eighth consecutive quarter of record sales and profits. These results were driven by positive Retail segment ‘comps’ at every brand and continued double-digit growth in our Wholesale and Subscription segments,” said Richard A. Hayne, Chief Executive Officer. “Our customers continue to respond favorably to our fashion assortments. This gives us confidence in URBN’s ongoing success.”

Urban Outfitters shares fell 4.6% to trade at $79.11 on Thursday.

These analysts made changes to their price targets on Urban Outfitters following earnings announcement.

Wells Fargo analyst Ike Boruchow maintained the stock with an Equal-Weight rating and raised the price target from $75 to $80. UBS analyst Jay Sole maintained the stock with a Neutral and raised the price target from $80 to $82. Considering buying URBN stock? Here’s what analysts think:

Photo via Shutterstock

Trending

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.